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Supplementary Material S2.1.1. Details of the search strategy 
 Before deduplication After deduplication 
Embase.com  3021 3013 
Medline (in OvidSP) 2034 843 
Web-of-Science 957 335 
Cochrane central  54 2 
PubMed publisher 43 32 
Google Scholar 200 152 
Total  6309 4377 
 
Embase.com  
('carotenoid'/de OR 'xanthophyll'/de OR (carotenoid* OR xanthophyl* OR xanthofyl* OR xantophyl* OR xantofyl* OR lutein* OR epilutein*):ab,ti) AND 
((((('cardiovascular disease'/exp NOT ('cardiovascular disease'/exp/dm_cn OR 'congenital disorder'/exp)) OR ((cardiovascular OR cardiac OR heart OR vascular OR 
cardiometabolic) NOT congenital):ab,ti) OR 'non insulin dependent diabetes mellitus'/de OR ((diabetes NEAR/6 ('type 2' OR 'type ii' OR 'non insulin' OR 
noninsulin)) OR ((glucose OR insulin) NEAR/3 (level* OR concentration OR  plasma OR blood OR serum OR metabolism OR tolerance OR intolerance OR 
sensitivit* OR insensitivity* OR resistance OR homeosta*))  ):ab,ti) OR (hypertension/exp OR (('blood pressure') OR hypertensi* OR ((cholesterol OR LDL* OR 
HDL* OR triglyceride* OR lipoprotein* OR lipid*) NEAR/3 (plasma OR blood OR serum OR level* OR profile*)) OR hyperlip* OR dyslip*):ab,ti) OR (obesity/exp 
OR 'body mass'/de OR 'body fat'/de OR 'waist circumference'/de OR 'waist hip ratio'/de 'Metabolic Syndrome X'/de OR 'dual energy X ray absorptiometry'/de OR 
(obesity OR obese OR 'over weight' OR overweight OR adiposity OR dexa OR dxa OR  'dual energy X ray absorptiometry' OR 'dual x ray absorptiometry' OR 
‘metabolic syndrome’ OR ‘body mass index’ OR BMI OR Quetelet OR (body NEXT/1 (composition* OR fat* OR weight*)) OR 'ponderal index' OR (weight 
NEXT/1 gain*) OR ‘abdominal fat’ OR (fat NEAR/3 (mass OR percentage*)) OR skinfold* OR (waist NEAR/3 (hip OR circumference*))):ab,ti) OR (autacoid/de 
OR chemokine/exp OR 'prostaglandin derivative'/de OR 'C reactive protein '/de  OR (autacoid* OR chemokine* OR prostaglandin* OR ((inflammat*) NEAR/3 
(marker* OR mediator*)) OR 'C reactive protein' OR 'creactive protein' OR crp OR 'c reaction protein'):ab,ti) OR ('anthropometric parameters'/de OR 'body 
height'/de OR 'body size'/de OR 'head circumference'/de OR (((body) NEAR/3 (height OR size)) OR 'head circumference' OR (height NEAR/3 age)):ab,ti)) OR 
('respiratory tract disease'/exp OR 'respiratory function'/exp OR 'lung function test'/exp OR 'cystic fibrosis'/de OR (((respirat* OR breath* OR pulmonar* OR lung* 
OR airway* OR bronchopulmon*) NEAR/3 (disease* OR function* OR disorder* OR obstruct*)) OR COPD OR bronchitis):ab,ti) OR ('mental disease'/exp OR 
Epilepsy/exp OR cognition/exp OR 'mental function'/de OR 'brain function'/de OR memory/de OR (((cognit* OR learn* OR brain* OR neurolog* OR mental*) 
NEAR/3 (disorder* OR disease* OR function* OR develop* OR impair*)) OR memor* OR dyslex* OR (Attention NEAR/3 Defic*) OR adhd OR epilep* OR 
cognit* OR dement*):ab,ti)  OR ('nonalcoholic fatty liver'/de OR ((nonalcoholic OR 'non alcoholic' ) NEAR/3 ('fatty liver' OR steatohepatitis)):ab,ti)) AND 
(Epidemiology/exp OR 'cohort analysis'/de OR 'prospective study'/de OR 'follow up'/de OR 'longitudinal study'/de OR 'retrospective study'/de OR 'case control 
study'/de OR 'intervention study'/de OR 'clinical study'/de OR 'clinical trial'/exp OR (((Hazard OR odds OR risk*) NEXT/1 Ratio*) OR ((Prospectiv* OR Populat* 
OR Observat* OR Retrospect* OR intervent* OR clinical) NEXT/1 (stud* OR trial*)) OR (case* NEAR/3 control*) OR (Cross NEXT/1 section*)):ab,ti) NOT 
([animals]/lim NOT [humans]/lim) 
 
Medline (in OvidSP) 
("carotenoids"/ OR "xanthophyll"/ OR "Lutein"/ OR (carotenoid* OR xanthophyl* OR xanthofyl* OR xantophyl* OR xantofyl* OR lutein* OR epilutein*).ab,ti.) 
AND ((((exp "cardiovascular diseases"/ NOT (exp cardiovascular diseases/cn OR exp "Congenital Abnormalities"/)) OR ((cardiovascular OR cardiac OR heart OR 
vascular OR cardiometabolic) NOT congenital).ab,ti.) OR "Diabetes Mellitus, Type 1"/ OR ((diabetes ADJ6 ("type 2" OR "type ii" OR "non insulin" OR 
noninsulin)) OR ((glucose OR insulin) ADJ3 (level* OR concentration OR plasma OR blood OR serum OR metabolism OR tolerance OR intolerance OR sensitivit* 
OR insensitivity* OR resistance OR homeosta*))  ).ab,ti.) OR (exp hypertension/ OR (("blood pressure") OR hypertensi* OR ((cholesterol OR LDL* OR HDL* OR 
triglyceride* OR lipoprotein* OR lipid*) ADJ3 (plasma OR blood OR serum OR level* OR profile*)) OR hyperlip* OR dyslip*).ab,ti.) OR (exp obesity/ OR "Body 
Mass Index"/ OR exp "Body Fat Distribution"/ OR exp "Adipose Tissue"/ OR "waist circumference"/ OR "Waist-Hip Ratio"/ OR "Metabolic Syndrome X"/ OR 
"Absorptiometry, Photon"/ OR (obesity OR obese OR "over weight" OR overweight OR adiposity OR dexa OR dxa OR  "dual energy X ray absorptiometry" OR 
"dual x ray absorptiometry" OR "metabolic syndrome" OR "body mass index" OR BMI OR Quetelet OR (body ADJ (composition* OR fat* OR weight*)) OR 
"ponderal index" OR (weight ADJ gain*) OR "abdominal fat" OR (fat ADJ3 (mass OR percentage*)) OR skinfold* OR (waist ADJ3 (hip OR circumference*))).ab,ti.) 
OR (exp autacoids/ OR exp chemokines/ OR "C-Reactive Protein"/ OR (autacoid* OR chemokine* OR prostaglandin* OR (inflammat* ADJ3 (marker* OR 
mediator*)) OR "C reactive protein" OR "creactive protein" OR crp OR "c reaction protein").ab,ti.) OR ("Body Weights and Measures"/ OR "Body Constitution"/ 
OR "Skinfold Thickness"/ OR exp "body size"/ OR (((body) ADJ3 (height OR size)) OR head circumference OR (height ADJ3 age)).ab,ti.) OR (exp "respiratory tract 
diseases"/ OR exp "Respiratory Physiological Phenomena"/ OR exp "Respiratory Function Tests"/ OR "cystic fibrosis"/ OR (((respirat* OR breath* OR pulmonar* 
OR lung* OR airway* OR bronchopulmon*) ADJ3 (disease* OR function* OR disorder* OR obstruct*)) OR COPD OR bronchitis).ab,ti.) OR (exp "Mental 
Disorders"/ OR exp Epilepsy/ OR exp cognition/ OR exp "Mental Processes"/ OR exp memory/ OR exp "Memory Disorders"/ OR (((cognit* OR learn* OR brain* 
OR neurolog* OR mental*) ADJ3 (disorder* OR disease* OR function* OR develop* OR impair*)) OR memor* OR dyslex* OR (Attention ADJ3 Defic*) OR adhd 
OR epilep* OR cognit* OR dement*).ab,ti.)  OR (((nonalcoholic OR 'non alcoholic' ) ADJ3 ('fatty liver' OR steatohepatitis)).ab,ti.)) AND (exp Epidemiologic 
Studies/ OR "Intervention Studies"/ OR "clinical trial".pt. OR (((Hazard OR odds OR risk*) ADJ Ratio*) OR ((Prospectiv* OR Populat* OR Observat* OR 
Retrospect* OR intervent* OR clinical) ADJ (stud* trial*)) OR (case* ADJ3 control*) OR (Cross ADJ section*)).ab,ti.) NOT (exp animals/ NOT humans/) 
 
Cochrane central  
((carotenoid* OR xanthophyl* OR xanthofyl* OR xantophyl* OR xantofyl* OR lutein* OR epilutein*):ab,ti) AND ((((((cardiovascular OR cardiac OR heart OR 
vascular OR cardiometabolic) NOT congenital):ab,ti) OR ((diabetes NEAR/6 ('type 2' OR 'type ii' OR 'non insulin' OR noninsulin)) OR ((glucose OR insulin) 
NEAR/3 (level* OR concentration OR  plasma OR blood OR serum OR metabolism OR tolerance OR intolerance OR sensitivit* OR insensitivity* OR resistance OR 
homeosta*))  ):ab,ti) OR (('blood pressure' OR hypertensi* OR ((cholesterol OR LDL* OR HDL* OR triglyceride* OR lipoprotein* OR lipid*) NEAR/3 (plasma OR 
blood OR serum OR level* OR profile*)) OR hyperlip* OR dyslip*):ab,ti) OR ((obesity OR obese OR 'over weight' OR overweight OR adiposity OR dexa OR dxa 
OR  'dual energy X ray absorptiometry' OR 'dual x ray absorptiometry' OR ‘metabolic syndrome’ OR ‘body mass index’ OR BMI OR Quetelet OR (body NEXT/1 
(composition* OR fat* OR weight*)) OR 'ponderal index' OR (weight NEXT/1 gain*) OR ‘abdominal fat’ OR (fat NEAR/3 (mass OR percentage*)) OR skinfold* 
OR (waist NEAR/3 (hip OR circumference*))):ab,ti) OR ((autacoid* OR chemokine* OR prostaglandin* OR ((inflammat*) NEAR/3 (marker* OR mediator*)) OR 
'C reactive protein' OR 'creactive protein' OR crp OR 'c reaction protein'):ab,ti) OR ((((body) NEAR/3 (height OR size)) OR 'head circumference' OR (height 
NEAR/3 age)):ab,ti)) OR ((((respirat* OR breath* OR pulmonar* OR lung* OR airway* OR bronchopulmon*) NEAR/3 (disease* OR function* OR disorder* OR 
obstruct*)) OR COPD OR bronchitis):ab,ti) OR ((((cognit* OR learn* OR brain* OR neurolog* OR mental*) NEAR/3 (disorder* OR disease* OR function* OR 
develop* OR impair*)) OR memor* OR dyslex* OR (Attention NEAR/3 Defic*) OR adhd OR epilep* OR cognit* OR dement*):ab,ti) OR (((nonalcoholic OR 'non 
alcoholic' ) NEAR/3 ('fatty liver' OR steatohepatitis)):ab,ti)) AND ((((Hazard OR odds OR risk*) NEXT/1 Ratio*) OR ((Prospectiv* OR Populat* OR Observat* OR 
Retrospect*) NEXT/1 stud*) OR (case* NEAR/3 control*) OR (Cross NEXT/1 section*)):ab,ti)  
 
Web-of-Science 
TS=(((carotenoid* OR xanthophyl* OR xanthofyl* OR xantophyl* OR xantofyl* OR lutein* OR epilutein*)) AND ((((((cardiovascular OR cardiac OR heart OR 
vascular OR cardiometabolic) NOT congenital)) OR ((diabetes NEAR/6 ("type 2" OR "type ii" OR "non insulin" OR noninsulin)) OR ((glucose OR insulin) 
NEAR/3 (level* OR concentration OR  plasma OR blood OR serum OR metabolism OR tolerance OR intolerance OR sensitivit* OR insensitivity* OR resistance OR 
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homeosta*))  )) OR (("blood pressure" OR hypertensi* OR ((cholesterol OR LDL* OR HDL* OR triglyceride* OR lipoprotein* OR lipid*) NEAR/3 (plasma OR 
blood OR serum OR level* OR profile*)) OR hyperlip* OR dyslip*)) OR ((obesity OR obese OR "over weight" OR overweight OR adiposity OR dexa OR dxa OR  
"dual energy X ray absorptiometry" OR "dual x ray absorptiometry" OR "metabolic syndrome" OR "body mass index" OR BMI OR Quetelet OR (body composition* 
OR body fat* OR body weight*) OR "ponderal index" OR (weight  gain*) OR "abdominal fat" OR (fat NEAR/3 (mass OR percentage*)) OR skinfold* OR (waist 
NEAR/3 (hip OR circumference*)))) OR ((autacoid* OR chemokine* OR prostaglandin* OR ((inflammat*) NEAR/3 (marker* OR mediator*)) OR "C reactive 
protein" OR "creactive protein" OR crp OR "c reaction protein")) OR ((((body) NEAR/3 (height OR size)) OR "head circumference" OR (height NEAR/3 age)))) 
OR ((((respirat* OR breath* OR pulmonar* OR lung* OR airway* OR bronchopulmon*) NEAR/3 (disease* OR function* OR disorder* OR obstruct*)) OR COPD 
OR bronchitis)) OR ((((cognit* OR learn* OR brain* OR neurolog* OR mental*) NEAR/3 (disorder* OR disease* OR function* OR develop* OR impair*)) OR 
memor* OR dyslex* OR (Attention NEAR/3 Defic*) OR adhd OR epilep* OR cognit* OR dement*)) OR (((nonalcoholic OR "non alcoholic") NEAR/3 ("fatty liver" 
OR steatohepatitis)))) AND ((((Hazard OR odds OR risk*)  NEAR/1 ratio*) OR ((Prospectiv* OR Populat* OR Observat* OR Retrospect*)  NEAR/1 stud*) OR 
(case* NEAR/3 control*) OR (Cross  section*))) NOT (Animal* NOT human*)) 
 
PubMed as supplied by publisher 
((carotenoid*[tiab] OR xanthophyl*[tiab] OR xanthofyl*[tiab] OR xantophyl*[tiab] OR xantofyl*[tiab] OR lutein*[tiab] OR epilutein*[tiab])) AND 
(((((cardiovascular OR cardiac OR heart OR vascular OR cardiometabolic) NOT congenital)) OR ((diabetes AND (type 2 OR type ii OR non insulin OR 
noninsulin)) OR ((glucose OR insulin) AND (level*[tiab] OR concentration OR plasma OR blood OR serum OR metabolism OR tolerance OR intolerance OR 
sensitivit*[tiab] OR insensitivity*[tiab] OR resistance OR homeosta*[tiab]))  )) OR (hypertension[mh] OR ((blood pressure) OR hypertensi*[tiab] OR ((cholesterol 
OR LDL*[tiab] OR HDL*[tiab] OR triglyceride*[tiab] OR lipoprotein*[tiab] OR lipid*[tiab]) AND (plasma OR blood OR serum OR level*[tiab] OR profile*[tiab])) 
OR hyperlip*[tiab] OR dyslip*[tiab])) OR (obesity[mh] OR Body Mass Index[mh] OR Body Fat Distribution[mh] OR Adipose Tissue[mh] OR waist 
circumference[mh] OR Waist-Hip Ratio[mh] OR Metabolic Syndrome X[mh] OR Absorptiometry, Photon[mh] OR (obesity OR obese OR over weight OR 
overweight OR adiposity OR dexa OR dxa OR  dual energy X ray absorptiometry OR dual x ray absorptiometry OR metabolic syndrome OR body mass index OR 
BMI OR Quetelet OR body composition*[tiab] OR body fat*[tiab] OR body weight*[tiab] OR ponderal index OR weight gain*[tiab] OR abdominal fat OR (fat 
AND (mass OR percentage*[tiab])) OR skinfold*[tiab] OR (waist AND (hip OR circumference*[tiab])))) OR (autacoids[mh] OR chemokines[mh] OR C-Reactive 
Protein[mh] OR (autacoid*[tiab] OR chemokine*[tiab] OR prostaglandin*[tiab] OR (inflammat*[tiab] AND (marker*[tiab] OR mediator*[tiab])) OR C reactive 
protein OR creactive protein OR crp OR c reaction protein)) OR (Body Weights and Measures[mh] OR Body Constitution[mh] OR Skinfold Thickness[mh] OR 
body size[mh] OR (((body) AND (height OR size)) OR head circumference OR (height AND age))) OR (respiratory tract diseases[mh] OR Respiratory Physiological 
Phenomena[mh] OR Respiratory Function Tests[mh] OR cystic fibrosis[mh] OR (((respirat*[tiab] OR breath*[tiab] OR pulmonar*[tiab] OR lung*[tiab] OR 
airway*[tiab] OR bronchopulmon*[tiab]) AND (disease*[tiab] OR function*[tiab] OR disorder*[tiab] OR obstruct*[tiab])) OR COPD OR bronchitis)) OR (Mental 
Disorders[mh] OR Epilepsy[mh] OR cognition[mh] OR Mental Processes[mh] OR memory[mh] OR Memory Disorders[mh] OR (((cognit*[tiab] OR learn*[tiab] 
OR brain*[tiab] OR neurolog*[tiab] OR mental*[tiab]) AND (disorder*[tiab] OR disease*[tiab] OR function*[tiab] OR develop*[tiab] OR impair*[tiab])) OR 
memor*[tiab] OR dyslex*[tiab] OR Attention Defic*[tiab] OR adhd OR epilep*[tiab] OR cognit*[tiab] OR dement*[tiab])) OR non alcoholic fatty liver*[tiab]) AND 
((Hazard Ratio*[tiab] OR odds Ratio*[tiab] OR risk Ratio*[tiab][tiab] OR Prospectiv*[tiab] OR Populat*[tiab] OR Observat*[tiab] OR Retrospect*[tiab] OR 
























Coronary heart disease         
Adults           
Ford (2000) Blood level* 
Logistic 





Q3: 0.81  
Q4: 0.61  
Q2: 1.40 
Q3: 1.44  
Q4: 1.02  
0.13  
(P trend) +++ 
Gey (2010) Blood level* NM Mean levels in cases 
vs. controls 
Coronary heart disease cases     0.51 +++ 
Hak (2003) Blood level 
Logistic 
regression 
Quintiles (based on 














(P trend) +++ 
Ito (2006) Blood level* Cox regression  Per (log) micromol/L 
Mortality from ischemic 
heart disease 
HR 0.82 0.42 1.58 0.55 +++ 
Kabagambe 
(2005) Dietary iintake* 
Logistic 














(P trend) +++ 
















Koh (2011) Blood level Logistic 
regression 
















Murr (2009) Blood level* Welch’s t- test 
Mean levels in cases 
























Blood level ANCOVA Mean levels in cases 
vs. controls 
Coronary heart disease     NS + 
Ruiz Rejon 
(2002) 
Blood level* NM Mean levels in cases 
vs controls 
Myocardial infarction  ↓   <0.05 + 
Street (1994) Blood level 
Logistic 
regression 









Tavani (2006) Dietary intake*  
Logistic 
regression 















Stroke           
Adults           
Ascherio 
(1999) 
Dietary intake Pooled logistic 
regression 
Quintiles   Total stroke RR 
Q2: 0.89  
Q3: 0.88  













    Ischemic stroke RR 
Q2: 0.82  
Q3: 0.80  
Q4: 0.93  
































(based on controls) 


























































Ito (2006) Blood level* Cox regression Per (log) micromol/L Mortality from stroke HR 0.72 0.37 1.37 0.32 +++ 
Combined cardiovascular events        
Adults           



















Sesso (2005) Blood level Logistic 
regression 
Quartiles Combined cardiovascular 














Mortality from cardiovascular diseases        
Adults           
Bates (2011) Blood level* Cox regression  Z-scores  Vascular disease mortality HR 0.90 0.75 1.08 0.3 + 
Buijsse (2008) Dietary intake Cox regression per  SD  Cardiovascular mortality RR 0.95 0.81 1.12 NS +++ 
Ito (2006) Blood level* Cox regression  Per (ln) micromol/L Cardiovascular mortality HR 0.79 0.52 1.19 0.27 +++ 
Mayne (2004) Blood level* Cox regression  
Above vs below 
median  Cardiovascular mortality HR 0.74 0.28 1.96 NS ++ 















Diabetes Mellitus type II        
Adults           
Hozawa (2006) Blood level* Cox PH  Per SD  
Type 2 diabetes mellitus 
(current smokers) 
HR 1.22 0.93 1.61 NS +++ 







































Wang (2006) Blood level* 
Logistic 
regression 













Metabolic syndrome        










Per 0.09 micromol/L MetS count score beta -0.18 -0.30 -0.06 <0.05 +++ 
Adults           
Beydoun 
(2011) 
Blood level* Logistic 
regression 
Per 0.16 micromol/L  MetS OR 0.82 0.68 0.99 <0.05 +++ 
  ZIP 
regression 
Per 0.16 micromol/L MetS count score beta -0.08 -0.12 -0.04 <0.05 +++ 
Coyne (2009) Blood level* 
Logistic 
regression 













  ANOVA Quartiles MetS components  RR    0.39 - 

















Sugiura (2008) Blood level 
Logistic 








(P trend) ++ 
Suzuki (2011) Blood level 
Logistic 








(P trend) ++ 









    MetS components 
(men only) 
OR    0.51  
(P trend) 
++ 
    MetS components 
(women only) 
OR    0.21  
(P trend) 
++ 
Footnote: *measured together with zeaxanthin; ↓: Negative association ↑: Positive association 
1Adjustment level was categorized as followed; unadjusted  –; 4 covariates or less +; 5 to 8 covariates ++, 9 or more covariates +++ 
ANCOVA: Analysis of covariance ANOVA: Analysis of variance, MetS: Metabolic Syndrome, PH: proportional hazards , OR: Odds Ratio, HR: Hazard Ratio, RR: Relative Risk, ZIP: zero-inflated Poisson regression , NM: not mentioned.  
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estimate   LL 95%CI  UL 95%CI p-value 
Adjustment 
level1 
Blood pressure          
Adults            
Coyne (2009) Blood level* 
Logistic 











(P trend) ++ 




Blood pressure categories 
(<119/<79; 120-129/80-84;  
130-139/85-89; >140/>90) 






regression Per SD Hypertension  HR 0.94 0.87 1.01 NS ++ 
Street (1994) Blood level T-test 
Mean levels 
in cases vs 
controls 












































 Beta -0.048   0.12 ++ 
    
Diastolic blood 
pressure 
 Beta -0.079   0.01 ++ 
Suzuki (2011) Blood level* 
Partial 




coefficient -0.059   NS ++ 
     women 
Correlation 
coefficient -0.019   NS ++ 




coefficient -0.108   NS ++ 
     women 
Correlation 
coefficient -0.062   NS ++ 
Atherosclerosis           
Adults                     
D'Odorico 




(carotid and femoral) OR    NS +++ 




(mm/18months)  Beta -0.07 -0.11 -0.03
5 <0.01 +++ 
Iribarren 
(1996) 







 OR 0.77 0.57 1.03 NS +++ 
Karppi (2011) Blood level ANCOVA Continuous 
Carotid IMT 
(quartiles) 























Nieto (2000) Blood level* ANCOVA 
Mean levels 
in cases vs. 
controls 
Carotid IMT      NS + 
Polidori (2007) Blood level ANOVA 
Mean levels 





  ↓   <0.01 +++ 
Xu (2012)A Blood level ANOVA 
Mean levels 
in cases vs. 
controls 
Carotid IMT   ↓   <0.01 - 
Zou (2011) Blood level 
Pearson 
correlation 
Continuous Carotid IMT left 
Correlation 
coefficient 
-0.112   NS + 
     right 
Correlation 
coefficient 
-0.256   p<0.01 + 
Zou (2014) Blood level 
Linear 
regression 
Continuous Carotid IMT  Beta -0.340   0.03 + 
Other cardiovascular outcomes         










































      NS + 
Inflammatory markers          






















(Q4 vs Q1-3) 
     NS - 
D'Adamo 
(2012) 
Blood level Regression Continuous sTNF-alphaR1  Beta -1300 -2605 -6 <0.05 +++ 










for 8 weeks 
vs. placebo 
C-reactive protein          NS randomized 
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Hozawa (2007) Blood level* Regression Per SD C-reactive protein  Beta -0.05   0.03 +++ 
    Fibrinogen  Beta -0.06   0.11 +++ 
    Leukocytes3  Beta -0.10   <0.01 +++ 





(per tertile increase) 
     0.23 ++ 
Sundl (2009) Blood level* 
Linear 
regression 
Continuous (log)IL-64   ↓   0.04 - 
    C-reactive protein      NS - 




C-reactive protein Men Beta (S) -0.094   0.36 +++ 
     Women Beta (S) -0.015   0.78 +++ 
    IL-6 Men Beta (S) -0.106   0.30 +++ 
     Women Beta (S) -0.129   0.02 +++ 
    TNF-alpha Men Beta (S) -0.104   0.31 +++ 




Blood level Linear 
regression 
Continuous (ln) C-reactive 
protein 
 Beta -0.95 -2.71 0.815 0.29 ++ 
    Fibrinogen  Beta -0.36 -1.22 0.505 0.41 ++ 











    NS randomized 
      20mg 
lutein 
  -0.14 0.02 0.25 <0.02 randomized 




for 12 weeks 
vs placebo 
C-reactive Protein 10 mg 
Correlation 
coefficient 
-0.45   <0.01 - 
     20 mg 
Correlation 
coefficient -0.44   <0.01 - 









Continuous (ln) C-reactive 
Protein 
 Beta -0.0160   0.55 +++ 
Xu (21012)A Blood level Spearman 
correlation 
Continuous IFN-gamm   Correlation 
coefficient 
0.096     NS + 
        IL-6   Correlation 
coefficient 





(20mg) for 3 
months, vs 
placebo 
IL-6 (pg/ml)  Beta -113.0 -265.05 39.11 0.14 randomized 










 -0.5801     <0.05 ++ 
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Growth and body composition         










Weight      NS randomized 
    Length      NS randomized 
    
Head 
circumference 
     NS randomized 
Masters (2007) Blood level* 
Linear 
regression 
Cord blood  Birth weight      NS ++ 
    Birth length      NS ++ 
    Head 
circumference 
     NS ++ 
Melikian 
(2001) 
Blood level* T-test Tertiles 
(T3 vs T1) 
Weight   ↑   <0.01 + 
    Weight velocity      NS + 
    Height   ↑   <0.01 + 
    Height velocity      NS + 






Continuous BMI       NS + 
    
Waist 
circumference 
     NS + 


























% fatty mass excess  
 
   1.00 - 
    Height      0.90 - 
    Weight      0.08 - 
    BMI   ↑   <0.05 - 
    brachial perimeter      0.07 - 
    waist perimeter   ↑   <0.05 - 
    hip perimeter      0.09 - 





















































    BMI   Q2: 0.01 Q2: -0.96 Q2: 0.97 0.99  +++ 
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(ln) BMI  Beta -0.097   <0.01 ++ 








-0.054   NS ++ 
     Women Correlation 
coefficient 





(10 or 20mg) 
for 12 weeks 
vs placebo  
BMI        0.85 randomized 
       Weight        0.47 randomized 
       
Waist 
circumference        0.64 randomized 
       Body fat %        0.30 randomized 











 -0.45     <0.05 - 
        BMI  
Correlation 
coefficient 
 -0.44     <0.05  - 
Insulin resistance          








HOMA-IR      NS + 
    Fasting glucose      NS + 
    Fasting insulin      NS + 





(ln)HOMA-IR  Beta -0.011 -0.058 0.036 0.64 ++ 
    (ln) fasting glucose  Beta -0.012 -0.045 0.020 0.45 ++ 
    (ln) fasting insulin  Beta -0.008 -0.008 0.036 0.72 ++ 










    
2-hour postload 
plasma glucose   ↓   
0.03  
(P trend) +++ 
    fasting insulin   ↓   
<0.01 
(P trend) +++ 























(P trend) ++ 
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status      0.46 +++ 
  Regression 
Continuous 
(ln) Fasting glucose  Beta -0.00105 -0.00252 0.00042
5 0.18 +++ 
    2-hour glucose  Beta -0.00050 -0.00124 0.00024485 0.20 +++ 




Blood level Spearman 
correlation 
Continuous HbA1c < 7.1%  Correlation 
coefficient 






Continuous HbA1c < 7.1%  
Correlation 
coefficient 
-0.13   NS - 
Hozawa (2006) Blood level* 
Linear 
regression 





Beta -0.01 -0.7744 0.75445 0.98 +++ 
     
Non-
smokers 
Beta -0.27 -0.6816 0.14165 0.19 +++ 
    HOMA-IR 
Current 
smokers 
Beta 0.03 -0.2052 0.26525 0.80 +++ 
     
Non-
smokers 























































(P trend) +++ 
Sugiura (2006) Blood level Logistic 
regression 















0.37 (P trend) +++ 






 Beta -0.018   0.57 ++ 










-0.009   NS ++ 
     women 
Correlation 
coefficient 





(20mg) for 3 
months, vs 
placebo 
Blood glucose      0.66 randomized 
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Blood lipids           






Continuous Total-c      NS + 
    HDL-c      NS + 
    LDL-c      NS + 
Coyne (2009) Blood level* Logistic 
regression 


























Olea (2012) Dietary intake* T-test Sufficient vs 
insufficient 
intake 
Total-c      0.08 - 
   HDL-c   ↓   0.01 - 
   LDL-c      0.3 - 
    Triglycerides      0.7 - 
Renzi (2012) Blood level Pearson 
correlation 
Continuous Total-c  Correlation 
coefficient 
0.21   <0.09 + 
    HDL-c  Correlation 
coefficient 
0.36   <0.01 + 
    LDL-c  
Correlation 
coefficient 
0.10   NS + 
    Triglycerides  
Correlation 
coefficient 




Blood level* Correlation Continuous 






0.42     0.065 - 




Total-c (>240mg/dl,  
200-239 mg/dl, <200 mg/dl) 




Sluijs (2009) Dietary intake* 
Linear 
regression 
































HDL-c  Beta 0.222   <0.01 ++ 
    Triglycerides  Beta 0.022   0.48 ++ 




(ln) (ln)Triglycerides men 
Correlation 
coefficient -0.051   NS ++ 
     women 
Correlation 
coefficient -0.093   NS ++ 
    HDL-c men Correlation 
coefficient 
0.124   <0.05 ++ 
     women Correlation 
coefficient 








(10 or 20mg) 
for 12weeks 
vs placebo 
Total-c         0.62 randomized 
    HDL-c          0.78 randomized 
    LDL-c          0.96 randomized 
    Triglycerides         0.56 randomized 
Wang (2014) Blood level* 
Linear 
regression 
Continuous (ln) HDL-c  Beta 0.2831   <0.01 +++ 
    (ln) LDL-c  Beta -0.1106   <0.01 +++ 
 Dietary intake* 
Linear 
regression 
Continuous (ln) HDL-c  Beta 0.0095   <0.01 +++ 
    (ln) LDL-c  Beta -0.0083   <0.01 +++ 
Xu (2012)A Blood level 
Spearman 
correlation Continuous HDL-c   
Correlation 
coefficient 0.021     NS + 
        LDL-c   
Correlation 
coefficient 0.018     NS + 
        Triglycerides   Correlation 
coefficient 






(20mg) for 3 
months, vs 
placebo 
LDL-c      0.27 randomized 
    HDL-c      0.95 randomized 
    Triglycerides      0.06 randomized 
Footnote: *measured together with zeaxanthin ↓: Negative association ↑: Positive association 
1Adjustment level was categorized as followed; unadjusted  –;  4 covariates or less +; 5 to 8 covariates ++, 9 or more covariates +++ 
2Different measures (carotid artery stiffness parameter, pressure-strain elasticity modulus, arterial compliance, pulse wave velocity, systolic maximum diameter minus diastolic minimum diameter) 
3Association with leukocytes was cross-sectional. 
4IL-6 available in n=35  
5Confidence interval calculated based on reported standard error. 
ANCOVA: Analysis of covariance,  ANOVA: Analysis of variance, IMT: Intima media thickness, HOMA: homeastasis model assessment, IR: Insulin resistance,  S: Standardized, 
INF: interferon, LPS: lipopolysaccharida, PBMCS: peripheral blood mononuclear cells, TNF: tumor necrosis factor, IL: interleukin, Ln: natural logarithm, c: cholesterol, OR: Odds Ratio, NM: not mentioned, NS: not significant 
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Supplementary Material S2.1.4. Details on applied quality score 
The quality score is composed of 5 items, and each item was allocated 0, 1 or 2 points. This allowed a total score between 0 and 10 
points, 10 representing the highest quality. The following items are included in the score: 
 
1. Study design 
0 for cross-sectional studies 
1 for longitudinal studies (retrospective or prospective) or non-randomized intervention studies 




0 if n <500  
1 if n 500 to 2000 
2 if n >2000  
 
Intervention studies 
0 if n<50  
1 is n 50 to 100 




0 if the study used a one-day food record, a one-day 24h recall, an inappropriate FFQ or if not reported 
1 if the study used an appropriate FFQ, multiple day food records or multiple 24h recalls 
2 if the study used a biomarker 
 
Intervention studies 
0 if the intervention was only dietary advice or supplement use was not blinded 
1 if the intervention (supplement) was adequately single-blinded 
2 if the intervention (supplement) is adequately double-blinded 
 
4. Outcome (see table below) 
 0 1 2 
Growth and adiposity    
Anthropometric and adiposity 
measures 
(e.g. weight, skinfold thickness) 
If self-reported, inappropriate 
measurement method or not 
reported   
If retrieved from medical 
records 
 
If appropriate measurement 
method was used as part of 
study protocol. 
Cardiovascular health    
Measurements  
(e.g. atherosclerosis, blood 
pressure (BFP)) 
If not reported or  inappropriate 
measurement method (e.g. at 
home BP measure) or self-
reported 
Basically appropriate 
measurement method, but not 
adequately performed, for 
example single measurement of 
BP or not measured at rest, or 
from medical records 
 
 
If appropriate measurement 
method was used as part of the 
study.  
For BP: minimum of 2 
measurements at rest 
 
Cardiovascular diseases 
(e.g. hypertension, events, 
mortality) 
If not reported or if diagnosis 
was based on a proxy for disease 
(e.g. use of medication not 
specific for the disease(e.g. beta-
blocking agents, anti-coagulants) 
or symptoms) 
If diagnosis was self-reported or 
from medical records 
If diagnosis was made in study 
using appropriate measurement 
method (see above) or from 
registries  
Metabolic health and 
inflammatory markers 
   
Lab measures 
(e.g. bloodlipids, insulin, 
inflammatory markers) 
Inappropriate measurement 
method, self-report or not 
reported  
If lab measurement was not 
performed as part of study (e.g. 
from medical records) or non-
fasting for insulin, glucose and 
lipids  
If lab measurement was 
performed as part of the  study 
and after 12h or overnight fast 
for lipids, glucose and insulin 
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Metabolic diseases  
(e.g. diabetes, metabolic 
syndrome) 
If not reported or if diagnosis 
was based on a proxy for disease 
(i.e. use of medication that is 
not specific to the disease  or 
symptoms) 
If diagnosis was self-reported or 
retrieved from reports (e.g. 
medical records) not collected 
specifically for study or was 
based on the use of disease-
specific medication (e.g. 
antidiabetic medication) 
If diagnosis was made during 
study using adequate test or 
official registries were checked 




0 if findings are not controlled** for at least age and gender 
1 if findings are controlled for age and gender  
2 if an intervention study is adequately randomized or if findings are additionally controlled for covariates:  
Dietary lutein: (minimally 4 out of 8) Blood level of lutein: (minimally 3 out of 6) 
- energy intake - smoking 
- supplement use  - other carotenoids 
- smoking - any measure of body weight (if this is not the outcome) 
- other carotenoids - physical activity 
- any measure of body weight (if this is not the outcome) - any measure of socioeconomic status 
- physical activity - race/ethnicity 
- any measure of socioeconomic status  
- race/ethnicity  
 
** ‘Controlled for’ here refers to: adjusted for in the statistical analyses (e.g. with multiple regression); stratified for in the analyses (e.g. boys and girls separately); or narrow 
selection criteria of study participants on this covariate (e.g. including only 7 year old children would count as sufficiently controlling for age and including girls only does 




Supplementary Material S2.1.5. Assigned quality scores for the included studies 





Almushatat (2006) 0 0 2 2 0 4 
Ascherio (1999) 1 2 1 2 2 8 
Bates (2011) 1 1 2 1 1 6 
Ben Amara (2014) 0 0 2 2 1 5 
Beydoun (2011) 0 2 2 2 2 8 
Beydoun (2012) 0 1 2 2 2 7 
Blondin (2013) 1 0 2 2 2 7 
Brighenti (2005) 0 0 2 2 0 4 
Buijsse (2008) 1 1 0 2 2 6 
Capeding (2010) 2 2 2 2 2 10 
Coyne (2005) 0 1 2 2 2 7 
Coyne (2009) 0 1 2 2 2 7 
D’Adamo (2012) 1 0 2 2 1 6 
D’Odorico (2000) 1 0 2 2 1 6 
Dwyer (2001)  1 0 2 2 2 7 
Ford (2000) 0 2 2 2 2 8 
Ford (2002) 0 2 2 2 2 8 
Gey (2010) 1 2 2 2 0 7 
Granado-Lorencio (2006) 1 0 2 2 0 51 
Graydon 2 1 1 2 2 8 
Hak (2003) 1 1 2 2 2 8 
Hak (2004) 1 0 2 2 2 7 
Hirvonen (2000) 1 2 0 2 2 7 
Hozawa (2006) 1 2 2 2 2 9 
Hozawa (2007) 1 2 2 2 2 91 
Hozawa (2009) 1 2 2 2 2 9 
Iribarren (1997) 0 0 2 2 2 6 
Ito (2006) 1 2 2 2 1 8 
Kabagambe (2005) 0 2 1 2 2 7 
Karppi (2011) 0 1 2 2 2 7 
Kataja-Tuomola (2011) 1 2 1 2 2 8 
Klipstein-Grobusch (2000) 0 0 2 2 1 5 
Knekt (2004) 1 2 0 2 2 7 
Koh (2011) 1 1 2 2 2 8 
Masters (2007)  0 0 2 2 1 5 
Mayne (2004) 1 0 2 2 1 6 
Melikian (2001) 1 0 2 2 0 5 
Montonen (2004) 1 2 1 1 2 7 
Murr (2009) 0 1 2 2 0 5 
Nakamura (2006) 0 1 2 2 2 7 
Nieto (2000)  1 0 2 2 1 6 
Olea (2012) 0 0 0 1 0 1 
Osganian (2003) 1 2 1 2 2 8 
Polidori (2007) 0 0 2 2 2 6 
Renzi (2012) 0 0 2 2 1 5 
Rerksuppaphol 0 0 2 1 0 3 
Ribaya-Mercado (1995) 0 0 2 2 0 4 
Rowley (2003 0 0 2 2 2 6 
Ruiz Rejon (2002) 0 0 2 2 0 4 
Sesso (2004) 1 1 2 2 2 8 
Sesso (2005) 1 1 2 2 2 8 
Shardell (2011) 1 2 2 2 2 9 
Sluijs (2009) 0 0 1 2 2 5 
Street(1994) 1 0 2 2 1 61 
Sugiura (2006) 0 1 2 2 2 7 
Sugiura (2008) 0 1 2 2 2 7 
Sundl (2009) 0 0 2 2 0 4 
Suzuki (2010) 0 0 2 2 2 6 
Suzuki (2011) 0 1 2 2 1 6 
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Tavani (2006) 0 1 1 2 2 6 
Tornwall (2000) 1 2 1 2 2 8 
Van Herpen-Broekmans (2004) 0 0 2 2 1 5 
Wang (2006) 1 1 2 1 2 7 
Wang (2013) 2 2 2 2 2 101 
Wang (2014) 0 2 2 2 2 81 
Waters (2009) 0 0 2 0 0 2 
Xu (2012)a 0 0 2 2 1 51 
Xu (2012)b 2 1 2 2 2 9 
Yeon (2011) 1 0 2 2 1 6 
Zou (2011) 0 0 2 2 1 5 
Zou (2014) 1 0 2 2 1 6 
1Highest attained QS, QS for other exposures/outcomes as following: 
Granado-Lorencio (2006): for dietary lutein QS=4 
Hozawa (2007): for leukocytes QS=8 
Street (1994): for blood pressure QS=5, for cholesterol QS=4 
Wang (2013): for body composition QS=8, for blood levels of lutein and inflammatory outcomes QS=5 
Wang (2014): for dietary lutein and CRP QS=7, for blood level lutein and blood lipids QS=7, for dietary lutein and blood lipids QS=6. 





Supplementary Material S2.2.1. Details of the search strategy 
 Before deduplication After deduplication 
Embase.com 3234 3211 
Medline in ovidsp 1559 834 
Web-of-Science 999 564 
PubMed publisher 57 51 
Cochrane central  27 0 
Google Scholar 200 159 
Total  6076 4819 
 
Embase.com 
(Choline/de OR 'choline alfoscerate'/de OR 'choline bitartrate'/de OR citicoline/de OR phosphorylcholine/de OR phosphatidylcholine/de OR ((beta NEXT/1 cholin*) OR 
'alpha lecithin' OR amonita OR 'b cholin' OR bilineurine OR biocholine OR biocolina OR 'brassel 1000' OR bursine OR ceraxon OR cholin OR choline  OR 
cholinephosphate OR cidifos OR cidiphos OR citicholine OR citicolin* OR cyticholin* OR cytocholine OR diacylglycerophosphocholine OR 
diacylglycerophosphorylcholine OR diacylphosphatidylcholine OR diphosphocholine OR 'egg lecithin' OR fagine OR fosfatidylcholine OR fosfolutein OR 
glycerophosphatidylcholine OR glycerophosphocholine OR glycerylphosphorylcholine OR granulestin OR hepacholine OR kelecin OR laevocholine OR lecithin* OR 
lecithol OR levocholine OR lipotril OR luridine OR maxicholine OR nicholin OR phosphatidylcholine* OR phosphocholine OR phospholipon OR phosphorylcholine  OR 
rexort OR sauran OR sincaline OR sinkron OR sintoclar OR somazina OR topcithin OR urocholine OR vegelecithin OR 'Vitamine B4'):ab,ti) AND (((('cardiovascular 
disease'/exp NOT ('cardiovascular disease'/exp/dm_cn OR 'congenital disorder'/exp)) OR ((cardiovascular OR cardiac OR heart OR vascular OR cardiometabolic) NOT 
congenital):ab,ti) OR 'non insulin dependent diabetes mellitus'/de OR ((diabetes NEAR/6 ('type 2' OR 'type ii' OR 'non insulin' OR noninsulin)) OR ((glucose OR 
insulin) NEAR/3 (level* OR concentration OR  plasma OR blood OR serum OR metabolism OR tolerance OR intolerance OR sensitivit* OR insensitivity* OR resistance 
OR homeosta*))  ):ab,ti) OR (hypertension/exp OR (('blood pressure') OR hypertensi* OR ((cholesterol OR LDL* OR HDL* OR triglyceride* OR lipoprotein* OR lipid*) 
NEAR/3 (plasma OR blood OR serum OR level* OR profile*)) OR hyperlip* OR dyslip*):ab,ti) OR (obesity/exp OR 'body mass'/de OR 'body fat'/de OR 'waist 
circumference'/de OR 'waist hip ratio'/de 'Metabolic Syndrome X'/de OR 'dual energy X ray absorptiometry'/de OR (obesity OR obese OR 'over weight' OR overweight 
OR adiposity OR dexa OR dxa OR  'dual energy X ray absorptiometry' OR 'dual x ray absorptiometry' OR ‘metabolic syndrome’ OR ‘body mass index’ OR BMI OR 
Quetelet OR (body NEXT/1 (composition* OR fat* OR weight*)) OR 'ponderal index' OR (weight NEXT/1 gain*) OR ‘abdominal fat’ OR (fat NEAR/3 (mass OR 
percentage*) OR skinfold* OR (waist NEAR/3 (hip OR circumference*))):ab,ti)) OR (autacoid/de OR chemokine/exp OR 'prostaglandin derivative'/de OR 'C reactive 
protein '/de  OR (autacoid* OR chemokine* OR prostaglandin* OR ((inflammat*) NEAR/3 (marker* OR mediator*)) OR 'C reactive protein' OR 'creactive protein' OR 
crp OR 'c reaction protein'):ab,ti) OR ('anthropometric parameters'/de OR 'body height'/de OR 'body size'/de OR 'head circumference'/de (((body) NEAR/3 (height OR 
size)) OR 'head circumference' OR (height NEAR/3 age)):ab,ti) OR ('respiratory tract disease'/exp OR 'respiratory function'/exp OR 'lung function test'/exp OR 'cystic 
fibrosis'/de OR (((respirat* OR breath* OR pulmonar* OR lung* OR airway* OR bronchopulmon*) NEAR/3 (disease* OR function* OR disorder* OR obstruct*)) OR 
COPD OR bronchitis):ab,ti) OR ('mental disease'/exp OR Epilepsy/exp OR cognition/exp OR 'mental function'/de OR 'brain function'/de OR memory/de OR (((cognit* 
OR learn* OR brain* OR neurolog* OR mental*) NEAR/3 (disorder* OR disease* OR function* OR develop* OR impair*)) OR memor* OR dyslex* OR (Attention 
NEAR/3 Defic*) OR adhd OR epilep* OR cognit* OR dement*):ab,ti)  OR ('nonalcoholic fatty liver'/de OR ((nonalcoholic OR 'non alcoholic' ) NEAR/3 ('fatty liver' OR 
steatohepatitis)):ab,ti)) AND (Epidemiology/exp OR 'cohort analysis'/de OR 'prospective study'/de OR 'follow up'/de OR 'longitudinal study'/de OR 'retrospective 
study'/de OR 'case control study'/de OR 'intervention study'/de OR 'clinical study'/de OR 'clinical trial'/exp OR (((Hazard OR odds OR risk*) NEXT/1 Ratio*) OR 
((Prospectiv* OR Populat* OR Observat* OR Retrospect* OR intervent* OR clinical) NEXT/1 (stud* OR trial*)) OR (case* NEAR/3 control*) OR (Cross NEXT/1 
section*)):ab,ti) NOT ([animals]/lim NOT [humans]/lim) 
 
Medline in ovidsp 
(Choline/ OR Glycerylphosphorylcholine/ OR exp Phosphatidylcholines/ OR (beta cholin* OR "alpha lecithin" OR amonita OR "b cholin" OR bilineurine OR biocholine 
OR biocolina OR "brassel 1000" OR bursine OR ceraxon OR cholin OR choline  OR cholinephosphate OR cidifos OR cidiphos OR citicholine OR citicolin* OR 
cyticholin* OR cytocholine OR diacylglycerophosphocholine OR diacylglycerophosphorylcholine OR diacylphosphatidylcholine OR diphosphocholine OR "egg lecithin" 
OR fagine OR fosfatidylcholine OR fosfolutein OR glycerophosphatidylcholine OR glycerophosphocholine OR glycerylphosphorylcholine OR granulestin OR hepacholine 
OR kelecin OR laevocholine OR lecithin* OR lecithol OR levocholine OR lipotril OR luridine OR maxicholine OR nicholin OR phosphatidylcholine* OR phosphocholine 
OR phospholipon OR phosphorylcholine  OR rexort OR sauran OR sincaline OR sinkron OR sintoclar OR somazina OR topcithin OR urocholine OR vegelecithin OR 
"Vitamine B4").ab,ti.) AND ((((exp "cardiovascular diseases"/ NOT (exp cardiovascular diseases/cn OR exp "Congenital Abnormalities"/)) OR ((cardiovascular OR cardiac 
OR heart OR vascular OR cardiometabolic) NOT congenital).ab,ti.) OR "Diabetes Mellitus, Type 1"/ OR ((diabetes ADJ6 ("type 2" OR "type ii" OR "non insulin" OR 
noninsulin)) OR ((glucose OR insulin) ADJ3 (level* OR concentration OR plasma OR blood OR serum OR metabolism OR tolerance OR intolerance OR sensitivit* OR 
insensitivity* OR resistance OR homeosta*))  ).ab,ti.) OR (exp hypertension/ OR (("blood pressure") OR hypertensi* OR ((cholesterol OR LDL* OR HDL* OR 
triglyceride* OR lipoprotein* OR lipid*) ADJ3 (plasma OR blood OR serum OR level* OR profile*)) OR hyperlip* OR dyslip*).ab,ti.) OR (exp obesity/ OR "Body Mass 
Index"/ OR exp "Body Fat Distribution"/ OR exp "Adipose Tissue"/ OR "waist circumference"/ OR "Waist-Hip Ratio"/ OR "Metabolic Syndrome X"/ OR 
"Absorptiometry, Photon"/ OR (obesity OR obese OR "over weight" OR overweight OR adiposity OR dexa OR dxa OR  "dual energy X ray absorptiometry" OR "dual x 
ray absorptiometry" OR "metabolic syndrome" OR "body mass index" OR BMI OR Quetelet OR (body ADJ (composition* OR fat* OR weight*)) OR "ponderal index" 
OR (weight ADJ gain*) OR "abdominal fat" OR (fat ADJ3 (mass OR percentage*)) OR skinfold* OR (waist ADJ3 (hip OR circumference*))).ab,ti.) OR (exp autacoids/ 
OR exp chemokines/ OR "C-Reactive Protein"/ OR (autacoid* OR chemokine* OR prostaglandin* OR (inflammat* ADJ3 (marker* OR mediator*)) OR "C reactive 
protein" OR "creactive protein" OR crp OR "c reaction protein").ab,ti.) OR ("Body Weights and Measures"/ OR "Body Constitution"/ OR "Skinfold Thickness"/ OR exp 
"body size"/ OR (((body) ADJ3 (height OR size)) OR head circumference OR (height ADJ3 age)).ab,ti.) OR (exp "respiratory tract diseases"/ OR exp "Respiratory 
Physiological Phenomena"/ OR exp "Respiratory Function Tests"/ OR "cystic fibrosis"/ OR (((respirat* OR breath* OR pulmonar* OR lung* OR airway* OR 
bronchopulmon*) ADJ3 (disease* OR function* OR disorder* OR obstruct*)) OR COPD OR bronchitis).ab,ti.) OR (exp "Mental Disorders"/ OR exp Epilepsy/ OR exp 
cognition/ OR exp "Mental Processes"/ OR exp memory/ OR exp "Memory Disorders"/ OR (((cognit* OR learn* OR brain* OR neurolog* OR mental*) ADJ3 (disorder* 
OR disease* OR function* OR develop* OR impair*)) OR memor* OR dyslex* OR (Attention ADJ3 Defic*) OR adhd OR epilep* OR cognit* OR dement*).ab,ti.)  OR 
(((nonalcoholic OR 'non alcoholic' ) ADJ3 ('fatty liver' OR steatohepatitis)).ab,ti.)) AND (exp Epidemiologic Studies/ OR "Intervention Studies"/ OR "clinical trial".pt. OR 
(((Hazard OR odds OR risk*) ADJ Ratio*) OR ((Prospectiv* OR Populat* OR Observat* OR Retrospect* OR intervent* OR clinical) ADJ (stud* trial*)) OR (case* ADJ3 
control*) OR (Cross ADJ section*)).ab,ti.) NOT (exp animals/ NOT humans/) 
 
Cochrane central  
(((beta NEXT/1 cholin*) OR 'alpha lecithin' OR amonita OR 'b cholin' OR bilineurine OR biocholine OR biocolina OR 'brassel 1000' OR bursine OR ceraxon OR cholin 
OR choline  OR cholinephosphate OR cidifos OR cidiphos OR citicholine OR citicolin* OR cyticholin* OR cytocholine OR diacylglycerophosphocholine OR 
diacylglycerophosphorylcholine OR diacylphosphatidylcholine OR diphosphocholine OR 'egg lecithin' OR fagine OR fosfatidylcholine OR fosfolutein OR 
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glycerophosphatidylcholine OR glycerophosphocholine OR glycerylphosphorylcholine OR granulestin OR hepacholine OR kelecin OR laevocholine OR lecithin* OR 
lecithol OR levocholine OR lipotril OR luridine OR maxicholine OR nicholin OR phosphatidylcholine* OR phosphocholine OR phospholipon OR phosphorylcholine  OR 
rexort OR sauran OR sincaline OR sinkron OR sintoclar OR somazina OR topcithin OR urocholine OR vegelecithin OR 'Vitamine B4'):ab,ti)  AND ((((((cardiovascular 
OR cardiac OR heart OR vascular OR cardiometabolic) NOT congenital):ab,ti) OR ((diabetes NEAR/6 ('type 2' OR 'type ii' OR 'non insulin' OR noninsulin)) OR 
((glucose OR insulin) NEAR/3 (level* OR concentration OR  plasma OR blood OR serum OR metabolism OR tolerance OR intolerance OR sensitivit* OR insensitivity* 
OR resistance OR homeosta*))  ):ab,ti) OR (('blood pressure' OR hypertensi* OR ((cholesterol OR LDL* OR HDL* OR triglyceride* OR lipoprotein* OR lipid*) NEAR/3 
(plasma OR blood OR serum OR level* OR profile*)) OR hyperlip* OR dyslip*):ab,ti) OR ((obesity OR obese OR 'over weight' OR overweight OR adiposity OR dexa OR 
dxa OR  'dual energy X ray absorptiometry' OR 'dual x ray absorptiometry' OR ‘metabolic syndrome’ OR ‘body mass index’ OR BMI OR Quetelet OR (body NEXT/1 
(composition* OR fat* OR weight*)) OR 'ponderal index' OR (weight NEXT/1 gain*) OR ‘abdominal fat’ OR (fat NEAR/3 (mass OR percentage*)) OR skinfold* OR 
(waist NEAR/3 (hip OR circumference*))):ab,ti) OR ((autacoid* OR chemokine* OR prostaglandin* OR ((inflammat*) NEAR/3 (marker* OR mediator*)) OR 'C reactive 
protein' OR 'creactive protein' OR crp OR 'c reaction protein'):ab,ti) OR ((((body) NEAR/3 (height OR size)) OR 'head circumference' OR (height NEAR/3 age)):ab,ti)) 
OR ((((respirat* OR breath* OR pulmonar* OR lung* OR airway* OR bronchopulmon*) NEAR/3 (disease* OR function* OR disorder* OR obstruct*)) OR COPD OR 
bronchitis):ab,ti) OR ((((cognit* OR learn* OR brain* OR neurolog* OR mental*) NEAR/3 (disorder* OR disease* OR function* OR develop* OR impair*)) OR memor* 
OR dyslex* OR (Attention NEAR/3 Defic*) OR adhd OR epilep* OR cognit* OR dement*):ab,ti) OR (((nonalcoholic OR 'non alcoholic' ) NEAR/3 ('fatty liver' OR 
steatohepatitis)):ab,ti)) AND ((((Hazard OR odds OR risk*) NEXT/1 Ratio*) OR ((Prospectiv* OR Populat* OR Observat* OR Retrospect*) NEXT/1 stud*) OR (case* 
NEAR/3 control*) OR (Cross NEXT/1 section*)):ab,ti)  
 
Web-of-Science 
TS=(((beta cholin* OR 'alpha lecithin' OR amonita OR 'b cholin' OR bilineurine OR biocholine OR biocolina OR 'brassel 1000' OR bursine OR ceraxon OR cholin OR 
choline  OR cholinephosphate OR cidifos OR cidiphos OR citicholine OR citicolin* OR cyticholin* OR cytocholine OR diacylglycerophosphocholine OR 
diacylglycerophosphorylcholine OR diacylphosphatidylcholine OR diphosphocholine OR 'egg lecithin' OR fagine OR fosfatidylcholine OR fosfolutein OR 
glycerophosphatidylcholine OR glycerophosphocholine OR glycerylphosphorylcholine OR granulestin OR hepacholine OR kelecin OR laevocholine OR lecithin* OR 
lecithol OR levocholine OR lipotril OR luridine OR maxicholine OR nicholin OR phosphatidylcholine* OR phosphocholine OR phospholipon OR phosphorylcholine  OR 
rexort OR sauran OR sincaline OR sinkron OR sintoclar OR somazina OR topcithin OR urocholine OR vegelecithin OR 'Vitamine B4'))   AND ((((((cardiovascular OR 
cardiac OR heart OR vascular OR cardiometabolic) NOT congenital)) OR ((diabetes NEAR/6 ("type 2" OR "type ii" OR "non insulin" OR noninsulin)) OR ((glucose OR 
insulin) NEAR/3 (level* OR concentration OR  plasma OR blood OR serum OR metabolism OR tolerance OR intolerance OR sensitivit* OR insensitivity* OR resistance 
OR homeosta*))  )) OR (("blood pressure" OR hypertensi* OR ((cholesterol OR LDL* OR HDL* OR triglyceride* OR lipoprotein* OR lipid*) NEAR/3 (plasma OR blood 
OR serum OR level* OR profile*)) OR hyperlip* OR dyslip*)) OR ((obesity OR obese OR "over weight" OR overweight OR adiposity OR dexa OR dxa OR  "dual energy 
X ray absorptiometry" OR "dual x ray absorptiometry" OR "metabolic syndrome" OR "body mass index" OR BMI OR Quetelet OR (body composition* OR body fat* OR 
body weight*) OR "ponderal index" OR (weight  gain*) OR "abdominal fat" OR (fat NEAR/3 (mass OR percentage*)) OR skinfold* OR (waist NEAR/3 (hip OR 
circumference*)))) OR ((autacoid* OR chemokine* OR prostaglandin* OR ((inflammat*) NEAR/3 (marker* OR mediator*)) OR "C reactive protein" OR "creactive 
protein" OR crp OR "c reaction protein")) OR ((((body) NEAR/3 (height OR size)) OR "head circumference" OR (height NEAR/3 age)))) OR ((((respirat* OR breath* OR 
pulmonar* OR lung* OR airway* OR bronchopulmon*) NEAR/3 (disease* OR function* OR disorder* OR obstruct*)) OR COPD OR bronchitis)) OR ((((cognit* OR 
learn* OR brain* OR neurolog* OR mental*) NEAR/3 (disorder* OR disease* OR function* OR develop* OR impair*)) OR memor* OR dyslex* OR (Attention NEAR/3 
Defic*) OR adhd OR epilep* OR cognit* OR dement*)) OR (((nonalcoholic OR "non alcoholic") NEAR/3 ("fatty liver" OR steatohepatitis)))) AND ((((Hazard OR odds 
OR risk*)  Ratio*) OR ((Prospectiv* OR Populat* OR Observat* OR Retrospect* OR clinical)  NEAR/1 (stud* OR trial*)) OR (case* NEAR/3 control*) OR (Cross  
section*))) NOT (Animal* NOT human*)) 
 
PubMed publisher 
(Choline[mh] OR Glycerylphosphorylcholine[mh] OR Phosphatidylcholines[mh] OR (beta cholin*[tiab] OR alpha lecithin OR amonita OR b cholin OR bilineurine OR 
biocholine OR biocolina OR brassel 1000 OR bursine OR ceraxon OR cholin OR choline  OR cholinephosphate OR cidifos OR cidiphos OR citicholine OR 
citicolin*[tiab] OR cyticholin*[tiab] OR cytocholine OR diacylglycerophosphocholine OR diacylglycerophosphorylcholine OR diacylphosphatidylcholine OR 
diphosphocholine OR egg lecithin OR fagine OR fosfatidylcholine OR fosfolutein OR glycerophosphatidylcholine OR glycerophosphocholine OR 
glycerylphosphorylcholine OR granulestin OR hepacholine OR kelecin OR laevocholine OR lecithin*[tiab] OR lecithol OR levocholine OR lipotril OR luridine OR 
maxicholine OR nicholin OR phosphatidylcholine*[tiab] OR phosphocholine OR phospholipon OR phosphorylcholine  OR rexort OR sauran OR sincaline OR sinkron 
OR sintoclar OR somazina OR topcithin OR urocholine OR vegelecithin OR Vitamine B4)) AND ((((cardiovascular diseases[mh] NOT (cardiovascular diseases[mh]cn OR 
Congenital Abnormalities[mh])) OR ((cardiovascular OR cardiac OR heart OR vascular OR cardiometabolic) NOT congenital)) OR Diabetes Mellitus, Type 1[mh] OR 
((diabetes AND (type 2 OR type ii OR non insulin OR noninsulin)) OR ((glucose OR insulin) AND (level*[tiab] OR concentration OR plasma OR blood OR serum OR 
metabolism OR tolerance OR intolerance OR sensitivit*[tiab] OR insensitivity*[tiab] OR resistance OR homeosta*[tiab]))  )) OR (hypertension[mh] OR ((blood pressure) 
OR hypertensi*[tiab] OR ((cholesterol OR LDL*[tiab] OR HDL*[tiab] OR triglyceride*[tiab] OR lipoprotein*[tiab] OR lipid*[tiab]) AND (plasma OR blood OR serum 
OR level*[tiab] OR profile*[tiab])) OR hyperlip*[tiab] OR dyslip*[tiab])) OR (obesity[mh] OR Body Mass Index[mh] OR Body Fat Distribution[mh] OR Adipose 
Tissue[mh] OR waist circumference[mh] OR Waist-Hip Ratio[mh] OR Metabolic Syndrome X[mh] OR Absorptiometry, Photon[mh] OR (obesity OR obese OR over 
weight OR overweight OR adiposity OR dexa OR dxa OR  dual energy X ray absorptiometry OR dual x ray absorptiometry OR metabolic syndrome OR body mass index 
OR BMI OR Quetelet OR (body composition*[tiab] OR body fat*[tiab] OR body weight*[tiab]) OR ponderal index OR (weight gain*[tiab]) OR abdominal fat OR (fat 
AND (mass OR percentage*[tiab])) OR skinfold*[tiab] OR (waist AND (hip OR circumference*[tiab])))) OR (autacoids[mh] OR chemokines[mh] OR C-Reactive 
Protein[mh] OR (autacoid*[tiab] OR chemokine*[tiab] OR prostaglandin*[tiab] OR (inflammat*[tiab] AND (marker*[tiab] OR mediator*[tiab])) OR C reactive protein 
OR creactive protein OR crp OR c reaction protein)) OR (Body Weights and Measures[mh] OR Body Constitution[mh] OR Skinfold Thickness[mh] OR body size[mh] 
OR (((body) AND (height OR size)) OR head circumference OR (height AND age))) OR (respiratory tract diseases[mh] OR Respiratory Physiological Phenomena[mh] OR 
Respiratory Function Tests[mh] OR cystic fibrosis[mh] OR (((respirat*[tiab] OR breath*[tiab] OR pulmonar*[tiab] OR lung*[tiab] OR airway*[tiab] OR 
bronchopulmon*[tiab]) AND (disease*[tiab] OR function*[tiab] OR disorder*[tiab] OR obstruct*[tiab])) OR COPD OR bronchitis)) OR (Mental Disorders[mh] OR 
Epilepsy[mh] OR cognition[mh] OR Mental Processes[mh] OR memory[mh] OR Memory Disorders[mh] OR (((cognit*[tiab] OR learn*[tiab] OR brain*[tiab] OR 
neurolog*[tiab] OR mental*[tiab]) AND (disorder*[tiab] OR disease*[tiab] OR function*[tiab] OR develop*[tiab] OR impair*[tiab])) OR memor*[tiab] OR dyslex*[tiab] 
OR (Attention AND Defic*[tiab]) OR adhd OR epilep*[tiab] OR cognit*[tiab] OR dement*[tiab]))) AND (Epidemiologic Studies[mh] OR Intervention Studies[mh] OR 
clinical trial.pt. OR ((Hazard Ratio*[tiab] OR odds Ratio*[tiab] OR risk Ratio*[tiab]) OR ((Prospectiv*[tiab] OR Populat*[tiab] OR Observat*[tiab] OR Retrospect*[tiab] 
OR intervent*[tiab] OR clinical) AND (studies[tiab] OR study[tiab] OR trial*[tiab])) OR (case*[tiab] AND control*[tiab]) OR (Cross section*[tiab]))) AND publisher[sb] 
 
Google Scholar  
 
Choline cardiac|heart|diabetes |hypertension|obesity|"body fat|mass|weight|height|size"|overweight|adiposity|COPD|bronchitis|"brain|mental 
disease|function"|Epilepsy|cognition|memory|adhd cohort|prospective|"follow up"|longitudinal|retrospective  
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Supplementary Material S2.2.2. Details on applied quality score 
The quality score is composed of 5 items, and each item was allocated 0, 1 or 2 points.  
This allowed a total score between 0 and 10 points, 10 representing the highest quality.  
The following items are included in the score: 
 
 
1. Study design 
0 for cross-sectional studies 
1 for longitudinal studies (retrospective or prospective) or non-randomized intervention studies 




0 if n <500  
1 if n 500 to 2000 
2 if n >2000  
 
Intervention studies 
0 if n<50  
1 is n 50 to 100 




0 if the study used a one-day food record, a one-day 24h recall, an inappropriate FFQ or if not reported 
1 if the study used an appropriate FFQ, multiple day food records or multiple 24h recalls 
2 if the study used a biomarker 
 
Intervention studies 
0 if the intervention was only dietary advice or supplement use was not blinded 
1 if the intervention (supplement) was adequately single-blinded 
2 if the intervention (supplement) was adequately double-blinded 
 
4. Outcome (see table below) 
 0 1 2 
Neurological 
Neurological diseases 
(ie. Parkinson, Alzheimer) 
If not reported or if diagnosis 
was based on a proxy for disease 
(e.g. use of medication that is 
not specific to the disease  or 
symptoms) 
If diagnosis was self-reported or 
retrieved from reports (e.g. 
medical record) not collected 
specifically for study or was 
based on the use of disease-
specific medication (e.g.L-dopa 
for Parkinson) 
If diagnosis was made during 
study using appropriate test or 
official registries were checked 
by a researcher 
    
Cognitive function tests 
(ie. MMSE, MDRS) 
If not reported or inappropriate 
test was used 
If appropriate test was done, 
but not as part of research 
protocol or by staff not 
qualified to do test. 
If appropriate test was done as 
part of research protocol. 
Pulmonary 
Pulmonary diseases (ie. Asthma, 
COPD) 
If not reported or if diagnosis 
was based on a proxy for disease 
(e.g. use of medication that is 
not specific to the disease  or 
symptoms) 
If diagnosis was self-reported or 
retrieved from reports 
(e.g.medical record) not 
collected specifically for study 
or was based on the use of 
disease-specific medication  
If diagnosis was made during 
study using appropriate test or 
official registries were checked 
by a researcher 
    
Pulmonary function tests 
(ie. FEV1, FVC) 
If not reported or inappropriate 
test was used 
If appropriate test was done, 
but not as part of research 
If appropriate test was done as 
part of research protocol. 
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protocol or by staff not 
qualified to do test. 
Growth and adiposity 
Anthropometric and adiposity 
measures 
(ie. Weight, skinfold thickness) 
If self-reported, inappropriate 
measurement method or not 
reported   
If retrieved from medical 
records 
If appropriate measurement 
method was used as part of 
study protocol. 
Cardiovascular health  
Measurements  
(ie. Atherosclerosis, blood 
pressure) 
If not reported or  inappropriate 
measurement method (e.g. at 
home blood pressure 
measurement) or self-reported 
Basically appropriate 
measurement method, but not 
adequately performed, for 
example single measurement of 
blood pressure or not measured 
at rest, or from medical records 
If appropriate measurement 
method was used as part of the 
study. 
For blood pressure: minimum 
of 2 measurements at rest. 
    
Cardiovascular diseases 
(ie hypertension, events, 
mortality) 
If not reported or if diagnosis 
was based on a proxy for disease 
(e.g. use of medication not 
specific for the disease (e.g.beta-
blocking agents, anti-coagulants) 
or symptoms) 
If diagnosis was self-reported or 
from medical records 
If diagnosis was made in study 
using appropriate measurement 
method (see above) or from 
registries  
Metabolic health and inflammatory markers 
Laboratory measures 
(ie. Lipids, insulin, inflammatory 
markers) 
Inappropriate measurement 
method, self-report or not 
reported  
If lab measurement was not 
performed as part of study 
(e.g.from medical records) or 
non-fasting for insulin, glucose 
and lipids  
If lab measurement was 
performed as part of the  study 
and after 12h or overnight fast 
for lipids, glucose and insulin 
    
Metabolic diseases  
(ie diabetes, metabolic 
syndrome) 
If not reported or if diagnosis 
was based on a proxy for disease 
(e.g. use of medication that is 
not specific to the disease  or 
symptoms) 
If diagnosis was self-reported or 
retrieved from reports 
(e.g.medical records) not 
collected specifically for study 
or was based on the use of 
disease-specific medication 
(e.g.antidiabetic medication) 
If diagnosis was made during 
study using adequate test or 
official registries were checked 
by a researcher 
 
5. Adjustments 
0 if findings are not controlled** for at least age and gender 
1 if findings are controlled for:  
- age 
- gender 
2 if an intervention study is adequately randomized or if findings are additionally controlled for covariates:  
Dietary choline: (min 4 out of 8) Blood level of choline: (min 3 out of 6) 
- energy intake - Cholesterol level 
- cholesterol intake - alcohol use  
- supplement use - any measure of body weight (if this is not the outcome) 
- alcohol use - physical activity 
- any measure of body weight (if this is not the outcome) - any measure of socioeconomic status 
- physical activity - race/ethnicity 
- any measure of socioeconomic status  
- race/ethnicity  
 
** ‘Controlled for’ here refers to: adjusted for in the statistical analyses (e.g. with multiple regression); stratified for in the analyses (e.g. boys and girls separately); or narrow 
selection criteria of study participants on this covariate (e.g. including only 7 year old children would count as sufficiently controlling for age and including girls only does 




Supplementary Material S2.2.3. Assigned quality scores for the included studies 




assessment Adjustment Total 
Benton (2004) 2 2 2 2 2 10 
Bertoia (2014) 1 1 1 2 2 7 
Bidulescu (2007) 1 2 1 2 2 8 
Boeke (2013) 1 1 1 2 2 7 
Buchman (2001) 0 0 2 0 0 2 
Carmichael (2010) 1 1 1 2 2 7 
Cheatham (2012) 2 1 2 2 2 9 
Chen (2013) 0 0 2 2 1 5 
Dalmeijer (2008) 1 2 1 2 2 81 
Davis (1980) 2 0 2 2 2 8 
Detopoulou (2008) 0 2 1 2 1 6 
Deuster (2002) 2 0 2 2 2 8 
Drachman (1982) 2 0 2 2 2 8 
Evans (2007) 2 0 2 1 2 7 
Ferrannini (2013) 1 2 2 2 1 8 
Floegel (2012) 1 2 2 1 2 8 
Harris (1983) 2 0 2 2 2 82 
Hogeveen (2013) 1 0 2 1 1 5 
Imajo (2012) 0 0 2 2 0 4 
Ivorra (2012) 0 0 2 0 1 3 
Jiang (2012) 2 0 2 1 2 7 
Kalhan (2010) 0 0 2 2 1 5 
Killgore (2009) 2 0 0 0 2 4 
Kupke (1983) 0 0 2 0 0 2 
Ladd (1993) 2 1 2 2 2 9 
Mapstone (2014) 1 0 2 2 1 6 
Meikle (2013) 0 1 2 2 1 63 
Mills (2014) 1 1 2 2 1 7 
Mohs (1980) 2 0 2 2 2 8 
Nurk (2012) 0 2 2 2 1 7 
Olthof (2005) 2 0 2 2 2 8 
Poly (2011) 2 1 1 2 1 7 
Ried (2013) 0 2 2 2 1 74 
Sanz-Cortés (2013) 0 0 2 2 1 5 
Schriewer (1984) 0 2 2 1 0 55 
Shaw (2004) 1 1 1 2 2 7 
Shaw (2014) 1 0 2 2 1 6 
Signore (2008) 1 0 2 2 2 7 
Simonsson (1982) 1 0 0 2 0 3 
Sitaram (1978) 2 0 2 2 2 8 
Sorgatz (1988) 2 1 2 2 2 9 
Stegemann (2014) 1 1 2 2 1 7 
Strain (2013) 0 0 2 2 1 5 
Spiers (1996) 2 1 2 2 2 9 
Veenema (2008) 2 0 0 2 2 6 
Villamor (2012) 1 1 1 2 2 7 
Wallace (2012) 2 0 2 2 2 8 
Wu (2012) 1 0 2 2 2 7 
Yan (2012) 0 0 2 2 1 56 
Zeisel (1991) 2 0 2 2 2 8 
1Score for cardiovascular outcomes. QS for metabolic outcomes is 6. 
2Score for intervention study. QS for longitudinal study is 5.  
3Score for USA cohort. QS for Australian cohort is 5. 
4Score for COPD. QS for asthma is 6.  
5Score for metabolic outcomes. QS for body composition and cardiovascular outcomes is 4. 




Supplementary Material S3.1.1. Food groups in PCA 
Food group Components 
Potatoes and other tubers Potatoes (cooked or fried) and french fries 
Vegetables Endive, purslane, turnip tops, lettuce, chard, spinach, chicory, eggplant, avocado, 
cucumber, paprika, corn, pickle, tomatoes, beans, snow peas, courgette, tomato sauce, 
carrots, beetroots, cabbages, mushrooms, green peas, onions, leek, garlic, bean sprouts, 
celery, atjar tjampoer and crudités 
Fruits Apple, strawberries, apricot, pineapple, red berries, banana, blackberries, lemon, grapes, 
raspberries, cherries, grapefruit, tangerine, peach, pear, prunes, orange, applesauce, kiwi, 
mango, rhubarb, melon, nectarine, canned fruit and dried fruit 
Dairy products - high fat Whole milk, full-fat yoghurt drink, full-fat yogurt, cheese 40-60+, cream cheese, full-fat 
quark, pudding, sour cream, whipped cream and crème fraiche 
Dairy products - low fat Skimmed and semi-skimmed milk, skimmed and semi-skimmed yoghurt drink, skimmed 
and semi-skimmed yogurt, cheese 20-30+ and  low-fat quark 
Cereals and cereal products - high-fiber Brown rice, whole wheat pasta, whole wheat/brown/rye bread, muesli, seitan, oatmeal, 
wheat germ, and bran 
Cereals and cereal products - low fiber White rice, couscous, bulgur, white bread, rusk, croissants, corn flakes, crackers, rice cake, 
toast, pancakes, raisin bread, bami and white pasta 
Meat and meat products Red meat, poultry, organ meat and meat products 
Fish and shellfish Fish, fish products and shellfish 
Eggs and egg products Egg (cooked or fried) 
Vegetable oils Olive oil, nut oil, salad oil, sesame oil, sunflower oil, soybean oil and peanut oil 
Margarine and butter Margarine (solid and liquid), butter 
Sugar, confectionary and cakes Chocolate, candy, chocolate sprinkles, cake, pastry and biscuits 
Snacks Peanuts, beer nuts, trail mix, pretzels and chips 
Coffee and tea Coffee, cappuccino, espresso, English tea, green tea and herbal tea 
Sugar containing beverages Coke/Fanta/Sprite soft drinks, isotonic drinks, fruit juices and vegetable juices 
Light soft drinks and water Coke/Fanta/Sprite light soft drinks and water 
Alcoholic beverages Beer, wine, mixed drinks and liquor 
Condiments and sauces Chili/tomato/barbecue/shaslick/peanut/garlic/whisky/soy/salad sauce, salad dressing, 
mayonnaise, fish/egg/meat/Russian salad, sandwich spread, marmite, salt, spices/herbs and 
flavor powder 
Soups and bouillon Soup or bouillon with or without meat, meal soup and lentil soup 
Nuts, seeds and olives 
 
Nut butter, tahini, poppy seed, sesame, pumpkin seeds, sunflower seeds, pine nuts, mixed 
seeds and olives 
Soy products Tofu, tempeh, soymilk, soy chunks, soy dessert, vegetable burgers and quorn 





Supplementary Material S3.1.2. Details of the multiple imputation procedure 
Software used SPSS 22.0 for Windows 
Imputation method and key settings Fully conditional specification (Markov chain Monte Carlo method) 
Maximum iterations 10 
No of imputed data sets created 10 
Variables included in the imputation procedure: 
(imputed or used as predictors of missing data) 
Maternal age, BMI, education level, parity, household income, marital status, 
gestational age at dietary assessment,  pregnancy related comorbidities, alcohol 
use during pregnancy, smoking during pregnancy, use of folic acid 
supplementation, blood levels folic acid,  stress during pregnancy, vomiting 
during pregnancy, feeling nauseous during pregnancy, ‘Vegetable, fish and oil’ 
dietary pattern, ‘Fruits, nuts and high-fiber cereals’ dietary pattern and 
‘Margarine, snacks and sugar’ dietary pattern 
Paternal age, BMI and education level 
Child gender, gestational age at birth, birth weight, weight and height at 8 
time points between age 1 and age 6 and age at all these measurements, 
diseases (wheezing, lower respiratory tract infections and eczema) between age 
6 months and 4 year, breastfeeding, hospitalization in first year of life, TV 
watching at age 2, TV watching at age 4, playing outside at age 4, 
participation in sports at age 6, BMI, total body fat percentage, 
android/gynoid fat mass ratio, fat free mass index and fat mass index at age 6  
Treatment of non-normally distributed variables Predictive mean matching 




Supplementary Material S3.1.3. Basic characteristics of participants before and after multiple imputation 
 Original data  Imputed data 
Maternal characteristics   
Age, y 31.7 ± 4.2 No missings 
Pre-pregnancy BMI, kg/m2 23.3 ± 3.9 23.3 ± 3.9 
Gestational age at enrolment, weeks 13.6 (9.9-21.5) No missings 
Education,    
    Primary or secondary 1,019 (38%) 1,044 (39%) 
    Higher 1,640 (62%) 1,651 (61%) 
    Missing 36 (1%)  
Household income,    
    <2200 (Euro) 591 (24%) 676 (25%) 
    >2200 (Euro) 1,893 (76%) 2,019 (75%) 
    Missing 211 (8%)  
Parity,    
    0 1,665 (62%) 1,667 (62%) 
    ≥1 1,026 (38%) 1,028 (38%) 
    Missing 4 (0.1%)  
Smoking,    
    Never during pregnancy 1,886 (76%) 2,044 (76%) 
    Until pregnancy was known 236 (9%) 260 (10%) 
    Continued throughout pregnancy 363 (15%) 391 (15%) 
    Missing 210 (8%)  
Alcohol,    
    Never during pregnancy 776 (31%) 838 (31%) 
    Until pregnancy was known 413 (17%) 451 (17%) 
    Continued throughout pregnancy 1,278 (52%) 1,406 (52%) 
    Missing 228 (9%)  
Folic acid use,    
    No 203 (9%) 266 (10%) 
    Start first 10 weeks 734 (33%) 901 (33%) 
    Start periconceptional 1,281 (58%) 1,528 (57%) 
    Missing 477 (18%)  
Total energy intake (FFQ), kcal/day 2,153 ± 503 No missings 
Stress during pregnancy, global severity index 0.12 (0.00-0.77) 0.12 (0.00-0.77) 
Child characteristics   
Gender, boys 1,351 (50%) No missings 




Supplementary Material S3.1.4. Basic characteristics of included and excluded participants 
 Participants in analysis Participants not in 
analysis 
Maternal characteristics   
Age, y 31.7 ± 4.2 30.5 ± 5.1 
Pre-pregnancy BMI, kg/m2 23.3 ± 3.9 23.1 ± 4.0 
Gestational age at enrolment, weeks 13.6 (9.9-21.5) 13.5 (9.5-27.8) 
Education,    
    Primary or secondary 1,019 (37.8%) 697 (50.7%) 
    Higher 1,640 (61.7%) 679 (49.3%) 
    Missing 36 (1.3%) 26 (1.9%) 
Household income,    
    <2200 (Euro) 591 (23.8%) 360 (33.1%) 
    >2200 (Euro) 1,893 (76.2%) 728 (51.9%) 
    Missing 211 (7.8%) 314 (22.4%) 
Parity,    
    0 1,665 (61.9%) 769 (55.2%) 
    ≥1 1,026 (38.1%) 623 (44.8%) 
    Missing 4 (0.1%) 10 (0.1%) 
Smoking,    
    Never during pregnancy 1,886 (75.9%) 875 (67.3%) 
    Until pregnancy was known 236 (9.5%) 113 (8.7%) 
    Continued throughout pregnancy 363 (14.6%) 313 (24.1%) 
    Missing 210 (7.8%) 101 (7.2%) 
Alcohol,    
    Never during pregnancy 776 (28.8%) 525 (40.7%) 
    Until pregnancy was known 413 (15.3%) 208 (16.1%) 
    Continued throughout pregnancy 1,278 (51.8%) 558 (43.2%) 
    Missing 228 (8.5%) 111 (8.5%) 
Folic acid use,    
    No 203 (9.2%) 192 (13.7%) 
    Start first 10 weeks 734 (33.1%) 380 (33.7%) 
    Start periconceptional 1,281 (57.8%) 555 (49.2%) 
    Missing 477 (17.7%) 275 (19.6%) 
Total energy intake (FFQ), kcal/day 2,153 ± 503 2,125 ± 539 





Supplementary Material S3.1.5. Associations between maternal dietary patterns and offspring fat free mass index and fat mass index at 6 years (n=2,520). 
 Fat Free Mass Index (SD)  
β (95% CI) 
Fat Mass Index (SD)  
β (95% CI) 
 Crude Multivariable modela Crude Multivariable modela 
‘Vegetable, fish and oil’  
dietary pattern  
    
    Quartile 1 – low adherence Reference Reference Reference Reference 
    Quartile 2 0.02 (-0.08, 0.12) -0.02 (-0.12, 0.08) -0.16 (-0.25, -0.08)* -0.07 (-0.16, 0.01) 
    Quartile 3 0.01 (-0.09, 0.11) -0.04 (-0.14, 0.07) -0.22 (-0.30, -0.13)* -0.09 (-0.17, -0.00)* 
    Quartile 4 – high adherence 0.07 (-0.03, 0.17) 0.00 (-0.10, 0.11) -0.24 (-0.32, -0.15)* -0.09 (-0.18, 0.00) 
    P for trend  0.35 0.79 <0.01 0.30 
‘Nuts, soy and high-fiber 
cereals’ dietary pattern 
    
    Quartile 1 – low adherence Reference Reference Reference Reference 
    Quartile 2 0.03 (-0.08, 0.13) 0.01 (-0.09, 0.11) -0.15 (-0.24, -0.06)* -0.06 (-0.14, 0.03) 
    Quartile 3 0.08 (-0.03, 0.18) 0.06 (-0.05, 0.16) -0.14 (-0.23, -0.05)* 0.01 (-0.08, 0.09) 
    Quartile 4 – high adherence 0.13 (0.03, 0.23)** 0.12 (-0.01, 0.23) -0.16 (-0.25, -0.07)* 0.04 (-0.05, 0.13) 
    P for trend  <0.01 <0.01 <0.01 0.25 
‘Margarine, snacks and sugar’ 
dietary pattern 
    
    Quartile 1 – low adherence Reference Reference Reference Reference 
    Quartile 2 0.06 (-0.04, 0.16) 0.01 (-0.10, 0.11) -0.01 (-0.09, 0.08) 0.02 (-0.06, 0.11) 
    Quartile 3 -0.01 (-0.10, 0.10) -0.10 (-0.23, 0.03) -0.01 (-0.08, 0.08) 0.03 (-0.08, 0.13) 
    Quartile 4 – high adherence 0.00 (-0.10, 0.10) -0.16 (-0.33, 0.01) -0.02 (-0.10, 0.07) 0.03 (-0.11, 0.17) 
    P for trend 0.66 <0.01 0.90 0.33 
Results from multivariable linear regression analyses, based on imputed data. Values are regression coefficients (95% confidence interval) and reflect differences in age- and gender specific SD scores of fat free mass index or fat mass index  of 
the child for quartiles 2 to 4, as compared to quartile 1.  
Trend tests were performed by using adherence score (SD scores) as a continuous variable in the model. 
a Multivariable model: adjusted for maternal age at intake, gestational age at dietary assessment, smoking during pregnancy, alcohol drinking during pregnancy, maternal folic acid use, maternal educational level, family income, parity, 
maternal pre-pregnancy BMI, maternal stress during pregnancy, gender of the child, breast feeding, watching television at 2 years of age and participation in sports at 6 years of age. 





Supplementary Material S4.1.1. Crude associations of lutein and beta-carotene intake at 13 months with body 
composition at age 61 
AG = android/gynoid, BMI = body mass index, FMI = fat mass index, FFMI = fat free mass index 
1Values are linear regression coefficients (95% confidence interval) and reflect the difference in outcome (age and gender specific SD scores) for mid-low, mid-high and high intake, as 
compared to low intake of energy and beta carotene adjusted lutein intake.  
*P<0.05, **P<0.01 
Continuous model reflects the difference in outcome (age and gender specific SD scores) per SD increase of energy and beta carotene adjusted lutein intake.  
Models are adjusted for age at dietary assessment.  
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Supplementary Material S4.1.2. Crude associations of lutein and beta-carotene intake at 13 months with 
cardiometabolic health at age 61 
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1Values are linear regression coefficients (95% confidence interval) and reflect the difference in outcome (age and gender specific SD scores) for mid-low, mid-high and high intake, as compared to 
low intake of energy and beta carotene adjusted lutein intake.  
*P<0.05, **P<0.01  
Continuous model reflects the difference in outcome (age and gender specific SD scores) per SD increase of energy and beta carotene adjusted lutein intake.  




Supplementary Material S4.2.1. Flow chart of participants  
Dutch children 
with participation 
in postnatal phase  
n=4,215 
 
   
 
 n=1,775 children excluded 
due to missing information 
on dietary intake at 1 year 
of age  
 
   





   
  n=395 children excluded 
due to no visit to the 
research centre at the age of 
6 years 
  




HDL-c  n=1,390 
TAG      n=1,387 
Insulin   n=1,383 
PPfat     n=1,639 
 
SBP      n=1,969 
DBP  n=1,969 
PWV  n=1,704 
 
Cardiometabolic 
risk factor score 
n=1,316 
 
Missing data on exposure and outcome were not imputed. 
Missing data on covariates was imputed using the fully conditional specification (Markov chain Monte Carlo method) and predictive mean matching. Maximum number of 





Supplementary Material S4.2.2. Original data versus imputed data (n=2,371)1 
 Original data  Imputed data 
Child characteristics   
Sex   
Boys 49.9 (1,183) No missings 
Girls 50.1 (1,188) No missings 
Gestational age at birth (weeks)2 40.1 (35.9 – 42.3) 40.1 (35.9 – 42.3) 
Birth weight (grams) 3492 (574) 3492 (574) 
Dietary energy intake (kcal/day) 1306 (347) No missings 
Cakes & confectionary intake (gr/day)2 22 (2 – 80) No missings 
Sugar-containing beverage (servings/week) 7 (0 – 53) No missings 
Introduction of complementary feeding   
0-3 months 4.5 (106) 4.5 (106) 
3-6 months 55.7 (1,316) 55.7 (1321) 
After 6 months 39.8 (941) 39.9 (945) 
Missing 0.3 (8) - 
History of allergy for cow's milk   
No 93.9 (2,188) 93.9 (2,226) 
Yes 6.1 (142) 6.1 (145) 
Missing 7.1 (41) - 
Hospitalization in the first year   
No 79.4 (1,514) 78.5 (1,860) 
Yes 20.6 (394) 21.6 (511) 
Missing 19.5 (463) - 
Breastfed   
Never 10.6 (227) 10.5 (250) 
Partially in the first 4 months 60.6 (1,296) 60.6 (1437) 
Exclusively for at least 4 months 28.8 (616) 28.8 (684) 
Missing 9.8 (232) - 
TV watching (hours/day) at age 2yrs   
Less than 1 50.9 (1,128) 50.4 (1,195) 
At least 1 49.1 (1,088) 49.6 (1,176) 
Missing 6.5 (155) - 
Total body fat percentage 23.6 (4.6) Not imputed 
Fat mass index 3.5 (2.4 – 6.3) Not imputed 
Android/gynoid ratio 0.24 (0.05) Not imputed 
Maternal characteristics   
Maternal age (years) 31.9 (4.2) No missings 
Age of partner (years) 34.1 (5.2) 34.1 (5.2) 
Mother BMI at intake (kg/m2) 24.1 (4.0) 24.2 (4.0) 
Folic acid use   
Never  7.7 (137) 8.1 (193) 
Periconceptionally 62.5 (1,116) 62.2 (1,475) 
Started in first 10 weeks 29.8 (532) 29.6 (702) 
Missing 24.7 (586) - 
Educational level   
Lower 34.5 (808) 34.8 (824) 
Higher 65.5 (1,536) 65.2 (1,547) 
Missing 1.1 (27) - 
Net household income   
<2200 euros  20.3 (419) 21.3 (505) 
>2200 euros 79.7 (1,640) 78.7 (1866) 
Missing 13.2 (312) - 
Maternal comorbidities   
Pre-pregnancy  2.9 (49) 3.5 (82) 
Pregnancy-related 7.2 (150) 7.6 (180) 
Smoking during pregnancy   
Never 79.1 (1,710) 79.0 (1,873) 
Until pregnancy was known 10.0 (216) 10.0 (238) 
Continued 10.9 (236) 11.0 (260) 
Missing 8.8 (209) - 
1Values are means (SD) or valid percentages (absolute numbers), unless indicated otherwise 2Values are medians (95% range) 
Due to rounding, numbers might not completely add up to total.  
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Supplementary Material S4.2.3. Association of sugar-containing beverage intake with BMI (kg/m2) at ages 2, 3, 4 
and 6, by sex (n=2,371) 
 
‡ Median intake within the category, energy-adjusted using the residual method and fixed to an intake of 1306 kcal/day. 
Values are linear regression coefficients (95% confidence intervals) and reflect the increase in BMI for medium and high sugar-containing beverage intake, as compared to the 
lowest category.  
Trend test was performed using categories of sugar-containing beverage intake as continuous variable in the model.  
Model A was adjusted for age at the measurements.  
Model B was additionally adjusted for gestational age at birth, birth weight (SDS), age of mother and father, net household income, maternal BMI, education, smoking, folic 
acid use, pre-pregnancy and pregnancy related comorbidities, child hospitalization in first year of life and history of allergy to cow’s milk. 
Model C contains all variables included in model B and was additionally adjusted for child’s intake of sugar, confectionary, cakes and pastry, breastfeeding, time of 
introduction of complementary feeding, total energy intake and hours of TV watching. 
*P-value <0.05; **P-value <0.01 
 
  
   Age 2   Age 3  
  Model A Model B Model C Model A Model B Model C 
Boys 
Low intake 
‡3 servings/week  Reference Reference Reference Reference Reference Reference 
 
Medium intake 




























Trend  p = 0.98 p = 0.75 p = 0.75 p = 0.94 p = 0.67 p = 0.67 
        
Girls 
Low intake 
‡3 servings/week  Reference Reference Reference Reference Reference Reference 
 
Medium intake 




























Trend  p = 0.02 p = 0.03 p = 0.03 p = 0.01 p < 0.05 p = 0.03 
   Age 4   Age 6  
  Model A Model B Model C Model A Model B Model C 
Boys 
Low intake 
‡3 servings/week  Reference Reference Reference Reference Reference Reference 
 Medium intake 




 (-0.21; 0.09) 
-0.06 




 (-0.28; 0.10) 
-0.06 
(-0.26; 0.14) 
 High intake 













Trend  p = 1.00 p=0.58 p=0.57 p = 0.66 p = 0.98 p = 0.92 
        
Girls 
Low intake 
‡3 servings/week  Reference Reference Reference Reference Reference Reference 
 
Medium intake 




























Trend  p < 0.01 p = 0.04 p = 0.03 p < 0.01 p = 0.06 p = 0.09 
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Supplementary Material S4.2.4. Association of sugar-containing beverage intake with body composition at age 6, 
stratified by sex (n=2,001)  
  Difference in total body fat percentage1 
SD change (95% CI) 
Difference in android/gynoid fat ratio1 
SD change (95% CI) 




n = 321 
Reference Reference Reference Reference Reference Reference 
 Medium intake 
‡8 servings/wk 













 High intake 
‡15 servings/wk 













Trend  p = 0.23 p = 0.40 p = 0.53 p = 0.93 p = 0.81 p = 0.77 




n = 339 
Reference Reference Reference Reference Reference Reference 
 Medium intake 
‡8 servings/wk 













 High intake 
‡15 servings/wk 













Trend  p = 0.01 p = 0.14 p = 0.25 p = 0.01 p = 0.08 p = 0.09 
‡ Median intake within the category, energy-adjusted using the residual method and fixed to an intake of 1306 kcal/day. 
1Values are linear regression coefficients (95% confidence interval) and reflect the difference in total body fat percentage (SDS) or android/gynoid fat ratio (SDS) for medium 
and high sugar-containing beverage intake, compared to the lowest category.  
Trend test was performed using categories of sugar-containing beverage intake as continuous variable in the model. 
Model A was adjusted for age at the measurements and for child height at age 6 (SDS) (for android/gynoid ratio and body fat percentage). 
Model B was additionally adjusted for gestational age at birth, birth weight (SDS), age of mother and father, net household income, maternal BMI, education, smoking, folic 
acid use, pre-pregnancy and pregnancy related comorbidities, child hospitalization in first year of life and history of allergy to cow’s milk. 
Model C contains all variables included in model B and was additionally adjusted for child’s intake of sugar, confectionary, cakes and pastry, breastfeeding, time of 





Supplementary Material S4.2.5. Associations of sugar-containing beverage intake at 13 months and weight and 
height at age 6, stratified by sex (n=2,371) 
  Difference in weight
1 
SD change (95% CI) 
Difference in height1 
SD change (95% CI) 






















Trend  p = 0.54 p < 0.05 
















‡15 servings/week  





Trend  p = 0.09 p = 0.19 
‡ Median intake within the category, energy-adjusted using the residual method and fixed to an intake of 1306 kcal/day. 
1Values are linear regression coefficients (95% confidence interval) and reflect the difference in weight (SDS) or height (SDS) for medium and high sugar-containing beverage 
intake, compared to the lowest category.  
Trend tests were performed using categories of sugar-containing beverage intake as continuous variable in the model. 
Model C was adjusted for age at the measurements, gestational age at birth, weight at birth (SDS), age of mother, age of biological father, BMI of mother at intake, education 
of mother, smoking of mother during pregnancy, net household income, pre-pregnancy and pregnancy related comorbidities, child hospitalization in first year of life and 
history of allergy to cow’s milk, child’s intake of sugar, confectionary, cakes and pastry, breastfeeding, time of introduction of complementary feeding, total energy intake and 
hours of TV watching. 






 Supplementary Material S4.2.6. Association of sugar-containing beverage intake with risk of overweight/obesity 
at ages 2, 3, 4 and 6, stratified by sex 
 
‡ Median intake within the category, energy-adjusted using the residual method and fixed to an intake of 1306 kcal/day. 
1Values are odds ratios (95% confidence interval) and reflect the risk for overweight/obesity for medium and high sugar-containing beverage intake, compared to the lowest 
category.  
Trend test was performed using categories of sugar-containing beverage intake as continuous variable in the model. 
Model A was adjusted for age at the measurements.  
Model B was additionally adjusted for gestational age at birth, birth weight (SDS), age of mother and father, net household income, maternal BMI, education, smoking, folic 
acid use, pre-pregnancy and pregnancy related comorbidities, child hospitalization in first year of life and history of allergy to cow’s milk. 
Model C contains all variables included in model B and was additionally adjusted for child’s intake of sugar, confectionary, cakes and pastry, breastfeeding, time of 
introduction of complementary feeding, total energy intake and hours of TV watching. 
  
 
 Risk of overweight/obesity1 




Age 2  
(n=1,885)   
Age 3 
(n=2,371)  
  Model A Model B Model C Model A Model B Model C 
Boys 
Low intake 
‡3 servings/week  Reference Reference Reference Reference Reference Reference 
 
Medium intake 




























Trend  p = 0.80 p = 0.67 p = 0.77 p = 0.49  p = 0.33 p = 0.36 
        
Girls 
Low intake 
‡3 servings/week  Reference Reference Reference Reference Reference Reference 
 
Medium intake 




























Trend  p = 0.10 p = 0.19 p = 0.27 p = 0.11 p = 0.20 p = 0.25 
   Age 4 
(n=2,371) 
  Age 6 
(n=2,371) 
 
  Model A Model B Model C Model A Model B Model C 
Boys 
Low intake 
‡3 servings/week Reference Reference Reference Reference Reference Reference 




























Trend  p = 0.27 p = 0.13 p = 0.10 p=0.99 p=0.73 p=0.75 
        
Girls 
Low intake 
‡3 servings/week  Reference Reference Reference Reference Reference Reference 
 
Medium intake 




























Trend  p = 0.18 p = 0.34 p = 0.45 p = 0.15 p = 0.42 p = 0.34 
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Supplementary Material S4.2.7. Association of absolute sugar-containing beverage intake with BMI (SD scores) 
at ages 2, 3, 4 and 6 stratified by sex (n=2,371) without total energy adjustment and standardization. 
  Age 2 Age 3 Age 4 Age 6 
Boys Low intake Reference Reference Reference Reference 
















Trend  p = 0.98 p = 0.75 p = 0.97 p =0.26 
      
Girls Low intake Reference Reference Reference Reference 
















Trend  p = 0.25 p = 0.04 p = 0.09 p=0.02 
Values are linear regression coefficients (95% confidence intervals) and reflect the increase in BMI (SD scores) for medium and high sugar-containing beverage intake, as 
compared to the lowest category.  
Trend test was performed using categories of sugar-containing beverage intake as continuous variable in the model.  
Adjustments were made for age at measurements, gestational age at birth, birth weight (SDS), age of mother and father, net household income, maternal BMI, education, 
smoking, folic acid use, pre-pregnancy and pregnancy related comorbidities, child hospitalization in first year of life and history of allergy to cow’s milk and child’s intake of 







Supplementary Material S4.2.8. Association of absolute sugar-containing beverage intake with body composition 
at age 6, stratified by sex (n=2,001) without total energy adjustment and standardization. 
  Difference in total body fat percentage 
SD change (95% CI) 
Difference in android/gynoid fat ratio 
SD change (95% CI) 
Boys Low intake Reference Reference 








Trend  p = 0.45 p = 0.24 
    
Girls Low intake Reference Reference 








Trend  p = 0.19 p = 0.05 
Values are linear regression coefficients (95% confidence interval) and reflect the difference in total body fat percentage (SDS) or android/gynoid fat ratio (SDS) for medium 
and high sugar-containing beverage intake, compared to the lowest category.  
Trend test was performed using categories of sugar-containing beverage intake as continuous variable in the model. 
Adjustments were made for age at measurements, gestational age at birth, birth weight (SDS), child height at age 6, age of mother and father, net household income, 
maternal BMI, education, smoking, folic acid use, pre-pregnancy and pregnancy related comorbidities, child hospitalization in first year of life and history of allergy to cow’s 




Supplementary Material S4.4.1. Components and cut-offs of the a priori diet quality score1 
Food group Cut-off level Summary of included items  
Vegetables ≥100 g Fresh vegetables, frozen or canned vegetables 
Fruit ≥150 g Fresh fruit, canned fruit without added sugar 
Bread and cereals ≥70 g Whole-wheat bread or crackers, oatmeal, muesli without added sugar 
Rice, pasta, potatoes, and legumes ≥70 g Boiled or steamed potatoes, whole-wheat pasta, couscous, whole-grain rice, legumes 
Dairy ≥350 g Semi-skimmed and skimmed milk and yogurt without added sugars, soy milk without 
added sugars, low-fat and reduced-fat cheeses (20+ and 30+) 
Meat, eggs and meat substitutes ≥35 g Low-fat meat, eggs, tofu, tempeh 
Fish ≥15 g Fresh or canned fish 
Fats and oils ≥25 g Low-fat margarine products (≤16g saturated fat and ≤1g trans-fat per 100g), vegetable oils, 
liquid cooking or frying fat 
Candy and snacks ≤ 20 g Ice cream, potato chips, cookies, candy bars, fried snacks, cake 
Sugar-sweetened beverages ≤ 100 g Soft drinks, lemonade 




Supplementary Material S4.4.2. Multivariable-adjusted associations of dietary patterns at 1 year of age with 
childhood height, weight, body fat percentage, and android/gynoid ratio at 6 years of age. 
 Weight (SDS) 
n =2,026 
Height (SDS) 
n = 2,026 
BF% (SDS) 
n = 1,980 
A/G ratio (SDS) 
n = 1,980 
 β (95%CI) β (95%CI) β (95%CI) β (95%CI) 
Diet score     
Per SD 0.06 (0.03; 0.10)** 0.05 (0.01; 0.09)* 0.00 (-0.03; 0.03) -0.00 (-0.04; 0.04) 
Q1 Reference Reference Reference Reference 
Q2 0.04 (-0.05; 0.13) -0.01 (-0.13; 0.10) 0.01 (-0.08; 0.10) -0.04 (-0.14; 0.06) 
Q3 0.04(-0.05; 0.14)  -0.02 (-0.14; 0.09) -0.05 (-0.14; 0.04) -0.06 (-0.16; 0.04) 
Q4 0.19 (0.10; 0.29)** 0.15 (0.03;0.27)* 0.02 (-0.08; 0.11) 0.01 (-0.10; 0.11) 
PCA Health-conscious 
pattern     
Per SD 0.03 (-0.01; 0.07) 0.01 (-0.04; 0.05) -0.01 (-0.04; 0.03) -0.01 (-0.05; 0.03) 
Q1 Reference Reference Reference Reference 
Q2 0.04 (-0.06; 0.13) 0.05 (-0.07; 0.16) 0.01 (-0.09; 0.10) 0.02 (-0.08; 0.12) 
Q3 0.12 (0.02;0.21)* 0.11 (-0.01; 0.22) -0.01 (-0.11; 0.08) 0.02 (-0.08; 0.12) 
Q4 0.13 (0.03;0.23)** 0.08 (-0.04; 0.20) -0.01 (-0.11; 0.08) -0.02 (-0.12; 0.09) 
PCA Western pattern     
Per SD 0.00 (-0.04; 0.04) 0.00 (-0.05; 0.05) -0.01 (-0.05; 0.04) 0.01 (-0.04; 0.06) 
Q1 Reference Reference Reference Reference 
Q2 -0.01 (-0.11; 0.08) -0.05 (-0.16; 0.07) 0.05 (-0.05; 0.14) 0.08 (-0.03; 0.18) 
Q3 0.11 (0.01; 0.20)* 0.04 (-0.07; 0.16) 0.03 (-0.07; 0.13) 0.08 (-0.02; 0.19) 
Q4 0.03 (-0.08; 0.14) 0.02 (-0.11; 0.15) -0.02 (-0.13; 0.09) 0.05 (-0.07; 0.17) 
RRR pattern 1     
Per SD 0.10 (0.06; 0.14)** 0.05 (0.00; 0.10)* 0.08 (0.04; 0.12)** 0.07 (0.02; 0.11)** 
Q1 Reference Reference Reference Reference 
Q2 0.09 (0.00;0.19)* 0.04 (-0.08; 0.15) 0.10 (0.01; 0.19)* 0.08 (-0.02; 0.18) 
Q3 0.14 (0.05;0.24)** 0.12 (0.00; 0.24)* 0.08 (-0.01; 0.18) 0.06 (-0.04; 0.16) 
Q4 0.23 (0.13;0.33)** 0.13 (0.01; 0.25)* 0.14 (0.04; 0.24)** 0.14 (0.03; 0.25)** 
RRR pattern 2     
Per SD 0.02 (-0.02; 0.06) 0.02 (-0.03; 0.07) -0.05 (-0.09;-0.01)** -0.05 (-0.09;-0.00)* 
Q1 Reference Reference Reference Reference 
Q2 -0.06 (-0.15; 0.04) -0.03 (-0.15; 0.09) -0.07 (-0.16; 0.03) -0.07 (-0.17; 0.03) 
Q3 0.11 (0.01; 0.21)* 0.13 (0.01; 0.25)* -0.06 (-0.16; 0.04) -0.03 (-0.14; 0.08) 
Q4 0.04 (-0.07; 0.15) 0.01 (-0.12; 0.15) -0.12 (-0.23; -0.02)* -0.12 (-0.23; 0.00) 
Values are regression coefficients that reflect the difference in outcome (age- and sex-adjusted SD scores) per 1 SD increase in exposure and for quartiles of exposure 
compared to the lowest quartile, based on imputed data. 
Models are adjusted for maternal age, BMI at enrollment, parity, folic acid supplement use, smoking and alcohol use during pregnancy; paternal smoking and education; 
household income; and child sex, breastfeeding in the first four months of life, timing of introduction of complementary feeding, age at dietary measurement, total energy 
intake at 1 year, and television watching at age 2 years. BF% and A/G ratio are additionally adjusted for child height. 
Abbreviations: BF%, body fat percentage; A/G ratio, android/gynoid ratio; PCA, principal component analyses; RRR, reduced rank regression 
*p<0.05, **p<0.01  
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 Supplementary Material S4.4.3. Associations of dietary patterns at 1 year of age with childhood body 




n = 2,026 or 1,649 
FMI (SDS) 
n = 1,980 or 1,609 
FFMI (SDS) 
n = 1,980 or 1,609 
 β (95%CI) β (95%CI) β (95%CI) 
Diet quality score (per SD)    
Crude model – total population 0.05 (0.02; 0.08)** 0.01 (-0.02; 0.04) 0.07 (0.03; 0.11)** 
Covariate adjusted (main model) – total population 0.06 (0.02; 0.09)** 0.02 (-0.01; 0.05) 0.06 (0.02; 0.10)** 
Covariate adjusted (main model) – weaned children  0.06 (0.02; 0.09)** 0.03 (-0.01; 0.06) 0.05 (0.00; 0.09)* 
Main model + baseline BMI –total population 0.04 (0.01; 0.07)* 0.01 (-0.02; 0.04) 0.05 (0.01; 0.08)* 
Health-conscious pattern (PCA) (per SD)    
Crude model – total population 0.04 (0.00; 0.07)* 0.00 (-0.03; 0.04) 0.05 (0.01; 0.09)* 
Covariate adjusted (main model) – total population 0.04 (0.01; 0.08)* 0.01 (-0.03; 0.04) 0.05 (0.01; 0.09)* 
Covariate adjusted (main model) – weaned children  0.03 (-0.01; 0.07) -0.00 (-0.04; 0.04) 0.03 (-0.02; 0.08) 
Main model + baseline BMI –total population 0.03 (-0.00; 0.07) 0.00 (-0.03; 0.03) 0.04 (0.00; 0.08)* 
Western pattern (PCA) (per SD)    
Crude model – total population 0.04 (-0.01; 0.08) 0.05 (0.01; 0.09)* 0.00 (-0.04; 0.05) 
Covariate adjusted (main model) – total population 0.00 (-0.04; 0.05) -0.01 (-0.05; 0.03) 0.02 (-0.04; 0.07) 
Covariate adjusted (main model) – weaned children  -0.03 (-0.09; 0.02) -0.04 (-0.09; 0.01) 0.00 (-0.06; 0.06) 
Main model + baseline BMI –total population 0.01 (-0.03; 0.05) -0.01 (-0.04; 0.03) 0.02 (-0.03; 0.07) 
RRR pattern 1 (per SD)    
Crude model – total population 0.14 (0.10; 0.18)** 0.15 (0.11; 0.19)** 0.08 (0.03; 0.13)** 
Covariate adjusted (main model) – total population 0.11 (0.07; 0.15)** 0.10 (0.06; 0.13)** 0.09 (0.04; 0.14)** 
Covariate adjusted (main model) – weaned children  0.09 (0.04; 0.13)** 0.08 (0.04; 0.12)** 0.07 (0.01; 0.12)* 
Main model + baseline BMI –total population 0.10 (0.06; 0.14)** 0.09 (0.06; 0.13)** 0.08 (0.03; 0.12)** 
RRR pattern 2 (per SD)    
Crude model – total population 0.00 (-0.04; 0.04) -0.06 (-0.10; -0.03)** 0.08 (0.03; 0.12)** 
Covariate adjusted (main model) – total population 0.02 (-0.02; 0.06) -0.03 (-0.07; 0.00) 0.07 (0.02; 0.11)** 
Covariate adjusted (main model) – weaned children  0.02 (-0.03; 0.06) -0.03 (-0.07; 0.01) 0.05 (-0.00; 0.10) 
Main model + baseline BMI –total population 0.01 (-0.03; 0.04) -0.04 (-0.07; -0.01)* 0.06 (0.01; 0.10)** 
Values are regression coefficients that reflect the difference in outcome (age- and sex-adjusted SD scores) per 1 SD increase in exposure, based on imputed data.  
Weaned children were defined as children who no longer receive breast milk or a substantial amount of infant formula (i.e., more than 500 kcal/d). 
Crude models are adjusted for child sex, age at dietary measurement and total energy intake at 1 year.  
Covariate models are additionally adjusted for maternal age, BMI at enrollment, parity, folic acid supplement use, smoking and alcohol use during pregnancy; paternal 
smoking and education; household income; and child breastfeeding in the first four months of life, timing of introduction of complementary feeding, and television watching 
at age 2 years. 
Baseline BMI adjusted models are additionally adjusted for BMI-SDS at the age of 1 year 
Abbreviations: BMI, body mass index; FMI, fat mass index; FFMI, fat-free mass index; PCA, principal component analyses; RRR, reduced rank regression 
*p<0.05, **p<0.01 
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